Development of antibodies against the Notch pathway ligand JAG1 using phage display technology by Marques, Gonçalo Rodrigues Puidival
I 
 
 
 
Gonçalo Rodrigues Puidival Marques 
 
Licenciado em Bioquímica 
 
  
  
  
  
   
  
  
Development of antibodies against the 
Notch pathway ligand JAG1 using 
phage display technology 
 
  
  
Dissertação para obtenção do Grau de Mestre em 
Biotecnologia 
 
 
  
  
  
  
Orientador: Doutora Ana Barbas, Bayer, iBET 
Co-orientador: Doutora Gabriela Silva, iBET 
 
 
 
 
  
  
  
Júri: 
 
 
Presidente:   Prof. Doutor Rui Oliveira, FCT-UNL 
     Arguente:   Doutor André Filipe da Costa Faustino, iBET  
 Vogal:   Doutora Ana Barbas, Bayer, iBET 
                      
        
  
  
  
  
  
 
                                    Setembro 2019 
II 
 
 
 
 
Gonçalo Rodrigues Puidival Marques 
 
Licenciado em Bioquímica 
 
  
  
  
  
   
  
  
Development of antibodies against the 
Notch pathway ligand JAG1 using 
phage display technology 
 
  
  
Dissertação para obtenção do Grau de Mestre em 
Biotecnologia 
 
 
  
  
  
  
Orientador: Doutora Ana Barbas, Bayer, iBET 
Co-orientador: Doutora Gabriela Silva, iBET 
 
 
 
 
 
  
  
  
Júri: 
 
 
Presidente:   Prof. Doutor Rui Oliveira, FCT-UNL 
     Arguente:   Doutor André Filipe da Costa Faustino, iBET  
 Vogal:   Doutora Ana Barbas, Bayer, iBET 
                      
        
  
  
  
  
 
                                  Setembro 2019 
III 
 
 
 
 
Development of antibodies against the Notch pathway ligand JAG1 using phage 
display technology 
 
 
 
 
 
  
  
  
  
  
  
  
  
  
  
  
Copyright Gonçalo Rodrigues Puidival Marques, FCT/UNL, UNL  
  
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
  
  
  
  
  
  
  
  
  
  
A Faculdade de Ciências e Tecnologia e a Universidade Nova de Lisboa têm o direito, perpétuo 
e sem limites geográficos, de arquivar e publicar esta dissertação através de exemplares 
impressos reproduzidos em papel ou de forma digital, ou por qualquer outro meio conhecido ou 
que venha a ser inventado, e de a divulgar através de repositórios científicos e de admitir a sua 
cópia e distribuição com objetivos educacionais ou de investigação, não comerciais, desde que 
seja dado crédito ao autor e editor. 
 
IV 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
V 
 
Acknowledgements 
 
Queria começar por agradecer à Doutora Ana Barbas por me ter recebido no seu laboratório e 
por me ter permitido fazer parte deste projecto desafiante, assim como toda a ajuda que me 
prestou durante este ano. 
Queria agradecer também à Doutora Gabriela Silva que foi incansável no seu apoio a vários 
níveis, que sempre demonstrou disponibilidade em me ajudar quando necessitava e que 
sempre fez o que estava ao seu alcance para que esta tese fosse bem-sucedida. 
Gostaria de agradecer à direcção do iBET por me ter permitido realizar o projecto de tese nas 
suas instalações. 
Um obrigado especial para a futura Doutora Joana Sales-Dias que teve uma paciência de 
santa para me explicar todas as minhas dúvidas e por me ter ensinado grande parte do que eu 
aprendi este ano. 
Obrigado a todos os membros que pertencem ou pertenceram ao laboratório satélite da Bayer 
Healthcare Pharma durante a minha presença. Um muito obrigado ao Hugo, Khrystyna e Bia 
pelo apoio e conhecimento que me transmitiram, e à Sofia Silva pelo contributo na correcção 
desta tese e pelos seus ensinamentos. Queria igualmente agradecer à Raquel e Clara pelo 
apoio técnico em alguns ensaios e a todos os restantes membros - Inês, Fernanda, Sofia 
Rebelo, Daniel, Bernardo, Marta, Susana, Lígia, Sandra, António - pelo excelente ambiente que 
criaram para que eu me pudesse sentir bem-vindo e parte do grupo. 
Queria agradecer a todos os meus amigos que me ajudaram a completar mais esta etapa na 
minha vida e que me têm vindo a acompanhar desde há muitos anos. 
Por fim, mas em primeiro queria agradecer à minha família em especial aos meus pais e ao 
meu irmão porque sem vocês eu não teria chegado aqui. 
 
Um Muito Obrigado a Todos!   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
VI 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
VII 
 
Abstract 
 
The Notch signaling pathway is a cell-to-cell communication system that plays crucial 
roles during the embryonic development and in the tissue homeostasis. In mammals, this 
pathway is constituted by four Notch receptors (Notch1-4) and five Notch ligands (DLL1, 3 and 
4, and JAG1 and 2). Binding of the ligands to the receptors in adjacent cells leads to the 
activation of the Notch pathway and the regulation of a multitude of genes that control many 
cellular processes such as stem cell self-renewal, cell differentiation, proliferation, and survival. 
Deregulated expression of Notch signaling components are observed in many cancers, 
including breast, and shown to be implicated in tumor growth, recurrence and drug resistance. 
JAG1 is one of the five Notch ligands that is overexpressed in aggressive cancers and mediates 
many of the Notch signaling tumorigenic functions. JAG1 overexpression promotes cancer cell 
survival, proliferation, migration, metastasis, cancer stem cell population maintenance, tumor-
associated angiogenesis, and allows tumor cells to escape the immune surveillance. 
The goal of this work was to develop specific anti-JAG1 antibodies using phage display 
technology. To achieve that we used the Human Single Fold scFv Tomlinson library I+J and 
recombinant JAG1-EGF3-Fc protein as antigen. After several rounds of selections, 84 scFv 
clones capable to recognize and bind to recombinant JAG1 proteins were isolated. The binding 
of the 84 scFvs towards the JAG1 was tested by ELISA assays using recombinant JAG1 
proteins. Additionally, the binding of anti-JAG1 scFvs to endogenous cellular JAG1 was tested 
by flow cytometry. Sequencing analysis of the selected clones allowed the identification of 19 
unique anti-JAG1 scFvs. One was reformatted into two anti-JAG1 IgGs: one with a glycosite in 
HCDR2 and the other without. These IgG molecules were characterized by ELISA and SDS-
PAGE, and our data showed that after reformatting they were no longer able to recognize 
JAG1.  
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Resumo 
 
A via de sinalização do Notch é um sistema de comunicação celular que desempenha 
um papel crucial no desenvolvimento embrionário e na homeostasia dos tecidos. Nos 
mamíferos, esta via é constituída por quatro receptores e cinco ligandos. A ligação dos 
ligandos aos receptores de células adjacentes ativa a via Notch e conduz à modulação da 
expressão de múltiplos genes que controlam vários processos celulares, tais como renovação 
das células estaminais, diferenciação, proliferação e sobrevivência celular. Vários componentes 
desta via encontram-se sobre-expressos em diferentes tipos de cancro e estão associados ao 
crescimento e recorrência tumoral, e à resistência contra medicamentos. O JAG1 é um dos 
cinco ligandos da via Notch que se encontra sobre-expresso em cancros agressivos e que 
medeia muitas das funções tumorais da via Notch. A sobre-expressão do JAG1 promove a 
sobrevivência, proliferação, migração, e invasão das células cancerosas, a manutenção das 
células estaminais cancerígenas, a angiogénese tumoral, e permite que as células tumorais 
escapem à vigilância imunológica. 
O objetivo deste trabalho consistiu em obter anticorpos específicos contra JAG1 usando a 
tecnologia de phage display. Para isso, utilizamos a biblioteca I + J scFv Tomlinson Human 
Single Fold e a proteína recombinante JAG1-EGF3-Fc como antigénio. Após várias rondas de 
seleção, foram isolados 84 clones contendo fragmentos de anticorpo (scFvs) capazes de 
ligarem a proteínas JAG1 recombinantes. A especificidade destes 84 scFvs foi testada em 
ensaios de ELISA utilizando proteínas recombinantes JAG1. A ligação dos scFvs anti-JAG1 ao 
JAG1 celular também foi analisada por citometria de fluxo. A análise da sequenciação destes 
clones permitiu a identificação de 19 scFv anti-JAG1 únicos. Um deles foi reformatado em dois 
anti-JAG1 IgGs: um com um local de glicosilação no HCDR2 e o outro sem esse local. Estas 
moléculas foram caracterizadas por ELISA e SDS-PAGE, e os nossos resultados mostraram 
que estes anticorpos perderam a capacidade de reconhecer a proteína JAG1 ao serem 
reformatados. 
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1. Introduction 
                       
1.1 Cancer 
Cancer is a complex disease caused by deregulation of various biologic functions 
(Hassanpour et al., 2017). It is believed that cancer results from the accumulation of mutations 
and epigenetic alterations (e.g. abnormal DNA methylation, histone modifications, and 
nucleosome positioning) that alter the expression of particular genes leading to an increase or 
decrease of their functional effects. Many factors can promote mutations, like the lifestyle 
(drinking alcohol, smoking, bad diets), chemical compounds, environmental chemical 
substances, viruses, bacteria, and radiation (Coyle et al., 2017; Hassanpour et al., 2017). 
Cancer has become one of the major health problems in the world in recent years (Ke 
et al., 2017; Siegel et al., 2018)(Figure 1.1). It is expected to be one of the major causes of 
death and the principal barrier to increasing life expectancy in the near future. There were 
approximately 18 million new cancer cases and 10 million cancer deaths worldwide in 2018, 
according to the Global Cancer Observatory (Siegel et al., 2018). In men, the most common 
types of cancer are prostate, lung, and colorectal cancer. Women, on the other hand, are most 
affected by breast, lung, uterine corpus, and colorectal cancer (Siegel et al., 2019).  
 
Figure 1.1. Global map presenting the national ranking of cancer as a cause of death in ages below 
70 years in 2015 (Siegel et al., 2019). 
In the United States prostate, lung and bronchus, and colorectal cancers account for 
42% of all cases in men, with prostate cancer alone being responsible for nearly 1 in 5 new 
diagnoses. For women, the 3 most common cancers are breast, lung, and colorectal, which 
collectively represent one-half of all new diagnoses; breast cancer (BC) alone accounts for 30% 
of all new cancer diagnoses in women (Figure 1.2). It is expected that in 2019 in the United 
States 1,762,450 new cases will be diagnosed, being breast, prostate, lung and colorectal 
cancers the main responsible (Siegel et al., 2019). 
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Figure 1.2. The ten leading cancer types for the estimated new cancer cases and deaths by Sex, 
United States, 2019. Estimates exclude basal cell and squamous cell skin cancers and in situ carcinoma 
except urinary bladder (Siegel et al., Cancer Statistics, 2019). 
In Portugal, according to the Global Cancer Observatory, there were 58199 new cancer 
cases and 28960 cancer deaths in 2018. Colorectal, breast, prostate, and lung cancers are the 
most common cancers diagnosed, with gastric cancer also showing a high incidence in both 
sexes (Figure 1.3). 
 
 
Figure 1.3. Number of new cancer cases in the portuguese population in 2018 for both sexes and 
all ages (International Agency for Research on Cancer - World Health Organization, 2018). 
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Nowadays there are many effective methods to treat the cancer disease, such as 
surgery, radiation, and chemotherapy, and also new methods are being developed to increase 
the likelihood of survival with minor side effects like immunotherapy (Ke et al., 2017). However, 
some types of cancer still have a high mortality rate, like lung cancer, that is responsible for the 
death of nearly 25% of all cancer cases, and prostate cancer with a mortality rate of 10% 
(Siegel et al, 2019). Also, BC has a high mortality rate with 1 in 7 women dying from this 
disease.  
 
1.1.1 Breast Cancer 
Breast cancer is the major type of cancer diagnosed among women worldwide, and the 
second leading cause of cancer death (Siegel et al., 2018; Siegel et al., 2019)(Figure 1.4). In 
women, approximately 1 in 4 cancer cases are BC, which is correlated with hereditary and 
genetic factors, but mainly with non-hereditary factors like the nutrition, anthropometry and 
physical activity (Siegel et al., 2018). Breast cancer is a highly heterogeneous group of 
genetical and epigenetical diseases, exhibiting a variety of clinical features (Riaz et al., 2013; 
Dai et al., 2017). 
 
 
Figure 1.4. Global maps presenting the most common type of cancer incidence in 2018 in each 
country among women (Siegel et al., 2018). 
Breast cancer can be classified into different subtypes based on the gene expression 
profile: basal-like, ErbB2+/human epidermal growth factor 2 (HER2)+, normal breast-like, luminal 
subtype A and luminal subtype B (Malhotra et al., 2010)(Figure 1.5).  
 
4 
 
Figure 1.5. Molecular classification of BC. Breast cancer can be divided into five different subtypes: 
basal-like; HER2+; normal breast like; luminal A and luminal B based on the gene expression profile 
(adapted from Malhotra et al., 2010). 
The luminal tumors are positive for the estrogen (ER) and/or progesterone (PR) 
hormone receptors, and the majority responds well to therapy. Luminal A tumors (ER+, PR+, 
HER-) which represent the most common BC subtype, are characterized by high expression 
levels of ER and/or PR receptors and low proliferation (Ozlem Yersal et al., 2014). Patients with 
luminal A BC have a good prognosis and a small relapse rate (Ozlem Yersal et al., 2014). The 
luminal B tumors (ER+, PR+, HER2+) have a more aggressive phenotype and higher proliferation 
rate than the luminal A tumors, which leads to a worse prognosis (Ozlem Yersal et al., 
2014)(Figure 1.6). HER2+ tumors are characterized by the expression of the HER2 receptor that 
promotes uncontrolled growth, proliferation, invasion, and metastasis of cancer cells. Though 
HER2+ have a more aggressive biological and clinical behavior (Figure 1.6), treatments that 
specifically target HER2, e.g. monoclonal antibodies Trastuzumab (Herceptin) and Pertuzumab 
(Perjeta), are very effective against this type of cancer. These treatments are so effective that 
the prognosis for HER2+ BC is actually quite good (Ozlem Yersal et al., 2014; Dai et al., 2015). 
Basal-like cancers, which are often found in women with BRCA1 mutations, are infiltrating 
ductal tumors with solid growth pattern, especially aggressive clinical behavior (Figure 1.6) and 
high rate of metastasis (Ozlem Yersal et al., 2014). These tumors are generally triple-negative 
breast cancers (TNBC) since they do not express the ER and PR hormones nor the HER2 
protein. However, they typically overexpress the epidermal growth factor receptor (EGFR) and 
different combinations of basal cytokeratins CK5, CK14, CK17 (Ozlem Yersal et al., 2014; Reis 
et al., 2006). Normal breast-like cancers are poorly characterized and have been grouped into 
the classification of intrinsic subtypes with fibroadenomas and normal breast samples, and 
usually do not respond to chemotherapy (Ozlem Yersal et al., 2014; Dai et al., 2015). This type 
of BC lacks the expression of ER, PR, and HER2 proteins, and can also be classified as TNBC 
but not basal-like since it is negative for CK5 and EGFR. The metastasis of BC usually occurs to 
the bones, lungs, liver, and brain (Ozlem Yersal et al., 2014).  
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Figure 1.6. Patient outcome based on BC subtypes. The luminal A and luminal B BCs are positive for 
ER and PR and usually have a Better prognosis. HER2+ BC carry a poor prognosis but respond well to 
target therapy. Basal-like BCs are often associated with the BRCA1 mutation and have the worse 
prognosis (adapted from Dai et al., 2015). 
 
1.2 Notch Signaling Pathway 
1.2.1 History of the Notch  
In March 1913, Thomas Hunt Morgan’s group identified a mutation in Drosophila, that 
they called “Notch”. This mutation was responsible for a loss of a wing margin tissue from the 
distal tip of the wing as described by John Dexter in 1914 (Kopan, 2012). Notch mutant flies 
also exhibited additional wing veins and bristle abnormalities (Kopan, 2012). In the 1930s 
Donald Poulson was the first one to connect Notch to development through his ground-breaking 
work on hemizygous Notch mutant embryos (Kopan, 2012). Notch functions as a receptor of a 
novel intracellular signaling pathway were established in the 1980s and 1990s (Kopan, 2012).  
 
1.2.2 Notch Signaling Pathway 
The Notch signaling is an evolutionarily conserved pathway present in most multicellular 
organisms that is crucial for a multitude of cellular processes, including proliferation, apoptosis, 
migration, growth, and differentiation, during embryonic and post-natal development by 
facilitating short-range signaling between cells in contact (Sethi et al., 2011). In mammals, this 
pathway is constituted by four Notch receptors (Notch1-4) and five Notch ligands (three Delta-
Like ligands, DLL1,3 and 4, and two Jagged ligands, JAG1 and 2)(Sethi et al., 2011; Bray., 
2016; Aster et al., 2017; Nowell et al., 2017; Meurette et al., 2018).  
The Notch signaling pathway is a cell-to-cell communication system that transduces 
extracellular signals to the nucleus (Figure 1.7). After its synthesis in the endoplasmic reticulum, 
during the exocytosis process, the Notch receptor is cleaved by convertases proteins at site 1 
(S1 cleavage), which regulates their trafficking and signaling activity (Logeat et al., 1998; 
Gordon et al., 2009; Kopan, 2012). In the Golgi complex, the receptors can be glycosylated by 
glycosyl-transferases. This glycosylation will determine how the receptors respond to different 
ligands (Kopan, 2012). 
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Figure 1.7. The Notch signaling pathway. When Notch ligands bind to Notch receptors on the adjacent 
cell surface, it elicits sequential cleavages of the receptors that realese the Notch intracellular domain 
leading to its migration to the nucleus to interact with DNA binding proteins, and driving the expression of 
target genes (Kopan, 2012). 
The activation of the Notch pathway is initiated when the transmembrane region of a 
ligand expressed in one cell physically interacts with the extracellular region of the receptor on 
an adjacent cell (Gray et al., 1999; Sethi et al., 2011). Upon ligand binding to the receptor, an 
unfolding of the juxtamembrane negative control region (NRR) of the receptor occurs, which 
allows access to the extracellular metalloprotease ADAM10 to remove the extracellular domain 
region of the receptor by cleaving at site 2 (S2 cleavage)(Brou et al., 2000; Sethi et al., 2011; 
Kopan, 2012).  
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A third cleavage occurs in the receptor when the γ-secretase complex cuts the 
transmembrane domain at site 3 (S3 cleavage)(Kopan, 2012), releasing the Notch intracellular 
domain (NICD) (Figure 1.7)(Schroeter et al., 1998; Mumm et al., 2000; Six et al., 2003; Sethi et 
al., 2011). The released NICD then migrates to the nucleus, due to its nuclear localization 
sequence, where it interacts with the DNA-binding protein CSL (CBF-1), recruiting the adaptor 
protein Mastermind-like (MAML). This complex then recruits the transcriptional co-activator 
HATp300 and basal components of the transcription machinery to modulate the expression of 
Notch target genes, such as the Hes and Hey family genes, p21, c-Myc (Figure 1.7)(Logeat et 
al., 1998; Wu et al., 2000; Iso et al., 2003; Kopan et al., 2009; Sethi et al., 2011; Kopan., 2012)   
The Notch pathway is extremely dosage-sensitive because there is no signal 
amplification step or secondary messengers to transmit the signal from the cell surface to the 
nucleus. Accordingly, every cleaved Notch molecule generates one signaling unit, and tuning 
the effectiveness of receptor-ligand interaction directly determines the amount of NICD in the 
nucleus and consequently the expression levels of the target genes (Kopan., 2012; Yamamoto 
et al, 2014). 
To achieve a productive activation of the Notch signaling pathway the binding of the 
Notch receptor with the ligand needs to be in Trans and never in Cis. This means that if one cell 
is expressing Notch receptors, the neighboring cells need to be expressing the ligand for 
activation of the Notch pathway to occur (Kopan, 2012). If cells express the receptor and the 
ligand simultaneously, which is often the case, the ratio between the number of receptors and 
ligands will determine if a cell is a signal sending or a signal receiving. If the receptors are more 
abundant than the ligands the cell is a signal receiving cell. In case the ligands are more 
abundant, then the cell is a signal sending cell (Kopan, 2012).  
 
1.2.3 Structure of the Notch Receptors and their Canonical 
Ligands 
As described above, in mammals the Notch signaling pathway is composed by four 
receptors (Notch receptors 1-4) and five canonical ligands, divided in two families: the Delta-
Like family which includes the DLL1, DLL3 and DLL4, and the Serrate (Jagged) family with the 
JAG1 and JAG2 ligands (Kopan et al, 2009). Each ligand can bind to each receptor and 
generates various distinct cellular responses (Andersson et al., 2011).  
The Notch receptors are single-pass type-1 transmembrane proteins divided into three 
domains: the extracellular domain (NECD), a transmembrane domain (TMD) and NICD 
(Yavropoulou et al., 2015)(Figure 1.8). The NECD contains 29 to 36 tandem epidermal growth 
factor-like repeats (EGFs) that can be calcium-binding domains that influence signaling 
productivity (Timmerman et al., 2008). Moreover, these  EGFs have great importance for the 
receptor structure and in the ligand-binding affinity (Cordle et al., 2008). A negative regulatory 
region (NRR) follows the EGFs region. It is composed of three cysteine-rich Lin12-Notch 
repeats (LNR) and a heterodimerization domain (HD)(Kopan et al., 2009).  
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The NRR inhibits Notch activation in the absence of ligands (Sethi et al., 2011). Next to 
the NRR region is the TMD that is followed by NICD. The NICD comprises a Rbp-associated 
Molecule (RAM) domain that is linked to seven intercellular ankyrin (ANK) repeats by a long and 
unstructured linker containing a nuclear localization sequence (NLS), which allows the nuclear 
translocation of the NICD. Right after the ANK domain is an extra NLS and a transactivation 
domain (TAD). In the C-terminal, a PEST sequence is present, that is responsible for the 
regulation of NCID stability and protein turnover (Kopan et al , 2009; Sethi et al., 2011). Notch 
receptor EGFs 11 and 12 are crucial in the binding between the receptor and the ligand (Rana 
et al., 2012) but additional EGFs may also contribute to ligand binding (Sharma et al., 2013). 
The receptors are translated in the endoplasmic reticulum (ER) and travel to the plasma 
membrane through the exocytic pathway while many posttranslational modification events 
occur. In the ER, the signal sequence at the N-terminal is cleaved off and the NECD undergoes 
sugar modifications mediated by protein glycosyltransferases (Rana and Haltiwanger, 2012; 
Yamamoto et al , 2014). 
Ligands are also type-1 transmembrane proteins. All ligands share a common ECD 
organization that comprises an N-terminal domain followed by a Delta/Serrate, and Lag2 (DSL) 
domain and tandem EGF repeats (Kopan et al., 2009; Yamamoto et al., 2014; Yamamoto et al., 
2010) (Figure 1.8). The DSL domain is highly conserved in the ligand family (Glittenberg et al., 
2006; Yamamoto et al., 2010). Different studies reported that alterations in the sequence of the 
amino acids of the DSL domain lead to a loss of function in Notch signaling, demonstrating that 
this domain is essential for ligand-receptor binding (Henderson et al., 1997; Henderson et al., 
1994; Tax et al., 1994). The EGF domains EGF1 and EGF2 were shown to contain regions 
(named DOS) important for efficient binding of the ligands to the receptors (Lafkas et al., 2015). 
The N-terminal region has also been reported to be important for the ligand function (Cordle et 
al., 2008). Based on these observations, as well as on studies on the Notch ligand interactions 
with the Notch receptors, a ligand minimal binding region required for the activation of the 
receptor that includes the N-terminal and the DSL domains and the EGF1-3 repeats was 
established (Henderson et al., 1994, 1997; Tax et al., 1994; Cordle et al., 2008). A single TMD 
and an intracellular domain (ICD), which presents very low sequence homology amongst the 
various ligands, follow the EGFs from the ligands (Pintar et al., 2007). 
The synthesis of the ligands occurs in the ER, these then pass through the Golgi 
complex, and are exocytosed. Vesicular trafficking to the membrane, endocytosis, and recycling 
of proteins play important roles in fine-tuning the signaling strength (Yamamoto et al., 2010; 
Charng et al., 2014; Yamamoto et al., 2014).  
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Figure 1.8. Schematic representation of Notch Receptors and Ligands. A- Representation of the 
four Notch receptors. B- Representation of the five Notch ligands. Notch receptors contain multiple 
extracellular EGF repeats. There are four mammalian Notch variations (Notch1-4) that differ in the number 
of repeats (29-36). EGF repeats 11-12 (yellow) and 24-29 (purple) mediate ligand interactions. Mammalian 
Notch proteins are cleaved by furin-type convertases, which convert the Notch polypeptide into an NECD- 
NICD (Notch extracellular domain-Notch transmembrane and intracellular domain) heterodimer that is 
connected by noncovalent interactions between the halves of the heterodimerization domain (Yavropoulou 
et al., 2015).  
1.2.4 Notch Signaling and Diseases 
The Notch signaling pathway plays crucial roles in a multitude of cellular processes. 
This includes the correct formation of the vascular system, development of T and B cells - either 
in central and peripheral lymphoid organs (Shang et al., 2016; Lamy et al., 2017), self-renewal 
and differentiation of the stem cells, commitment of lymphoid cell lineages (Clements et al., 
2011; Lamy et al., 2017), regulation of bone physiology and breast biology (Dufraine et al., 
2008; Yashiro-Ohtani et al., 2010; Clements et al., 2011; Shang et al., 2016; Lamy et al., 2017). 
Moreover, it participates in the innate immune responses and inflammation processes (Shang et 
al., 2016). In the intestine, due to the very high turnover rate of the intestinal epithelium cells, 
processes like proliferation, differentiation, and cell death must be tightly regulated in order to 
ensure homeostasis. The regulation of these processes is controlled by a relatively small 
number of signaling pathways, including the Notch pathway (Wilson et al., 2006). Importantly, 
the multiple roles of Notch signaling vary according to the tissue and cellular context (Wilson et 
al., 2006; Liu et al., 2010). 
Abnormal activation of this pathway is associated to various diseases. 
Haploinsufficiency of the Notch2 and JAG1 proteins are implicated in Alagille syndrome 
(Andersson et al., 2011), and mutations in the Notch2 and Notch3 genes have been linked with 
the Hajdu-Cheney and Cadasil syndromes, respectively (Regan et al., 2013; Lamy et al., 2017). 
JAG2 contributes to rheumatoid arthritis (Lamy et al., 2017), and deregulation of both JAG1 and 
JAG2 has been shown to be implicated in airway diseases (Lafkas et al., 2015). Moreover, 
diverse types of cancer have been associated with the malfunction of this pathway (Lamy et al., 
2017). 
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1.2.5 Notch as an Oncogene 
T-cell acute lymphoblastic leukemia (T-ALL) was the first type of cancer associated with 
the Notch oncogenic role, through a chromosomal translocation that promoted the constitutive 
expression of a truncated form of the Notch1 protein (Ellisen et al., 1991; Yamamoto et al,2014; 
Brzozowa-Zasada et al., 2017; Koch et al., 2018). Many studies have shown that the 
deregulation of the expression of the Notch receptors and/or ligands contribute to the 
development of solid cancers, such as brain, breast, liver, pancreatic, ovarian, cervical, 
prostate, kidney, melanoma, renal and lung (Dang et al., 2000; Fiona et al, 2000; Espinoza et 
al., 2013; Lamy et al., 2017; Sales-Dias et al., 2019).  
Notch signaling can promote tumor growth by increasing cancer cell proliferation and 
survival, cancer cell escape from immune surveillance, and inducing angiogenesis (Meurette 
and Mehlen, 2018). Notch signaling also provides epithelial tumor cells with migratory 
properties, facilitating metastasis (Sethi et al., 2011; Meurette and Mehlen., 2018). In addition,  
Notch signaling has been associated with cancer progression through the regulation of the 
epithelial-to-mesenchymal transition (a process needed for the metastasis of epithelial cancer 
cells) in cooperation with the TGFβ signaling (Zavadil et al., 2004; Timmerman et al., 2008) and 
β-catenin activity (Balint et al., 2005; Sethi et al., 2011). Moreover, Notch can also contribute to 
tumor growth and resistance by causing an immunosuppressive microenvironment by affecting 
the numbers and specific populations of immune cells (such as by increasing the number of 
regulatory T cells), cytokines, growth factors, among other factors (Meurette and Mehlen, 2018).  
As mentioned above, and as demonstrated in many studies, the Notch pathway tightly interacts 
with other signaling pathways, such as the NF-B, PI3K/AKT/mTOR, MAPK, Wnt, BPM, in 
various types of cancers to potentiate the oncogenic process. Importantly, the crosstalk 
between Notch and the various other signaling pathways is dictated by the cellular context (Liu 
et al., 2006; Espinoza et al., 2013; Fitzgerald et al, 2000; Espinoza et al., 2013). 
 
1.2.6 Notch as Tumor Suppressor 
Despite having an oncogenic role, some studies have shown that Notch can also have 
a tumor suppressor effect (Koch et al., 2018), as a consequence of its cell-intrinsic role in 
promoting cell cycle exit and differentiation, thus eliminating potential cancer stem cells (CSCs) 
and tumour-initiating cells (Wilson et al., 2006; Koch et al., 2007; Nowell et al., 2017). For 
example, the development and progression of squamous cell carcinomas in epithelial tissues is 
associated with loss of Notch1 and Notch2 receptors (South et al., 2014; Pickering et al, 2015; 
Nowell et al., 2017). Studies in small-cell lung cancer, identified recurrent loss-of-function 
mutations in Notch family genes, particularly Notch1, in human and mouse (George et al., 2016; 
Nowell et al., 2017).  
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Figure 1.9. Notch signaling oncogenic and tumor supressor effects. Notch signaling has many 
oncogenic effects, however, it can also have a tumor suppressive effect in the tumor such as the tumor-
promoting infammation (adapted from Aster et al., 2017). 
 
1.2.7 Notch in Breast Cancer 
Deregulated Notch signaling, through high expression and/or activation or its receptors 
or ligands, contributes to BC development (Politi et al., 2004; Mittal et al., 2009; Acar et al., 
2016; Brzozowa-Zasada et al., 2017; Lamy et al., 2017). The first evidence of Notch influence in 
BC was a study developed in mouse models where a virus insertion in Notch1 and Notch4 gene 
loci, causing its constitutive expression, lead to BC development (Gallahan et al., 1987; Anne 
Diévart, 1999; Lamy et al., 2017). 
Changes in the Notch pathway occur early in the disease progression, as demonstrated 
in several studies, showing that Notch signaling components are upregulated in early non-
invasive stages of BC (Mittal et al., 2009; Lamy et al., 2017).  
Notch1 overexpression has been documented to promote cell survival, proliferation, cell 
adhesion, migration, and invasion, and EMT in BC cell models (Xing et al., 2011; Bolós et al., 
2013; Shao et al., 2015) as well as in a wide variety of human breast carcinomas, namely in 
TNBC (Lamy et al., 2017). The carcinogenic effect of the Notch2 receptor is still unclear, 
however, high levels of this receptor have been detected in ER+ and luminal BCs (Fu et al., 
2010; Lamy et al., 2017). High levels of Notch3 have been identified in HER2-  BC (Hirose et al , 
1994). Some studies indicate that Notch4 is involved in BC recurrence through its ability to 
regulated BC stem cell (BCSC) activity (Harrison et al., 2010; Lamy et al., 2017). JAG1 and 
DLL4 are the two ligands shown to have the major interference in BC biology (Lamy et al., 
2017).  
JAG1 has been associated with increased BC relapse, drug resistance, and metastasis 
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(Reedijk et al., 2005; Rizzo et al., 2008; Lamy et al., 2017), and Notch activation via JAG1 is 
directly implicated in tumor growth by maintaining cancer stem cell (CSC) populations, 
promoting cell survival, proliferation, adhesion, metastasis, tumor angiogenesis and inhibiting 
apoptosis (Li, 2014; Andrieu et al., 2016; Lamy et al., 2017). DLL4 is associated with tumor 
angiogenesis (Dufraine et al., 2008), nodal and distant metastasis (Kontomanolis et al., 2014), 
and may confer drug resistance to BC cells (Lamy et al., 2017; Wang et al., 2017). JAG2 has 
also been implicated in the promotion of BC metastasis and self-renewal of BCSC (Xing et al., 
2011; Lamy et al., 2017). Simultaneous high expression of Notch1 and JAG1 correlate with poor 
prognostics in various BC subtypes (Reedijk et al., 2005; Mittal et al., 2009). Notch signaling 
can also cooperate with other oncogenes, such as Myc, in the promotion of BC (Efstratiadis et 
al., 2007; Mittal et al., 2009). 
 
1.2.8 Notch Inhibition as a Promising Approach for Cancer 
Treatment  
Since the Notch pathway has an important role in development, progression, recurrence 
and drug resistance of many different cancers, it is considered an important therapeutic target.  
The first approach to Notch inhibition was based on the use of γ-secretase inhibitors (GSI). 
These small molecules were responsible for reducing the levels of intracellular activated Notch 
by inhibiting the γ-secretase enzyme, responsible for the cleavage 3 of the Notch receptors 
during its activation (reviewed in Lamy et al., 2017). Various GSI molecules were developed 
and entered clinical trials. However, many clinical studies proved that these treatments caused 
serious side effects, especially gastrointestinal toxicity (Tolcher et al., 2012; Andersson et al, 
2014, Lamy et al., 2017). Besides participating in cancer development and progression when 
dysregulated, biologic levels of Notch activity are necessary for normal cellular processes like 
intestine cell renewal. Accordingly, the sustained inhibition of Notch receptors by GSIs 
significantly affect the intestines normal biology (Fre et al., 2005; Lamy et al., 2017). The 
combination of chemotherapy with GSIs presented promising results in various clinical studies 
supporting the hypothesis that Notch inhibition and chemotherapy may have a synergistic effect 
(Gilbert et al., 2010; Lamy et al., 2017). Recently, to prevent the binding between the 
overexpressed receptors and ligands, and subsequent hyperactivation of the Notch signaling, 
antibodies have been developed and entered into clinical trials in patients with advanced and/or 
metastatic cancers. Specific antibodies against Notch receptors (Sharma et al., 2012), and 
ligands have been developed during the last years with promising therapeutic effects (Davis et 
al., 2013; Li, 2014; Zheng et al, 2017; Lamy et al., 2017).  
 
 
1.3 JAG1 
JAG1 is one of the five canonical ligands of the Notch signaling pathway (Li., 2014; 
Grochowski et al., 2016). In 1995 the rat homolog ligand was cloned for the first time and 
named JAG1 due to the similarity to the Drosophila gene serrate, and the first discovered 
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function of JAG1 was the prevention of muscle cell differentiation (Lindsell et al., 1995; 
Grochowski et al., 2016). In humans, the JAG1 gene was mapped on the short arm of 
chromosome 20 in 1997 (Grochowski et al., 2016). Later on, mutations in JAG1 were 
demonstrated to cause the Alagille syndrome, an autosomal dominant multisystem disorder (Li 
et al., 1997; Grochowski et al., 2016). 
The JAG1 gene consists of 26 exons, encoding a protein with 1218 amino acid residues 
of approximately 124 kDa (Oda et al., 1997; Grochowski et al., 2016). It is a type-1 
transmembrane protein with a small intracellular domain (ICD), a transmembrane domain (TMD) 
and a large extracellular domain (ECD)(Figure 1.10). The ECD is divided into four motifs. A 21-
amino acid signal peptide to ensure that after synthesis the protein migrates to the cell 
membrane surface. An N-terminal region comprising a C2 domain that binds to phospholipid 
bilayers (Chillakuri et al., 2013). A DSL domain essential for the binding to the Notch receptors 
(as well as to the CD46 complement regulatory protein essential for the function of helper T 
cells (Friec et al., 2012)), followed by 16 EGF repeats, important for increasing the affinity to the 
Notch receptors (mostly EGF1 and EGF2). A cysteine-rich region (CRD) that is necessary to 
create the disulfide bonds responsible for protein stabilization. A C-terminus with a PDZ-ligand 
motif linked with the induction of intrinsic reverse signaling within the ligand expressing cells (Li, 
2014; Guarnaccia et al., 2004; Kopan et al, 2009; Chillakuri et al., 2012; Grochowski et al , 
2016). The TMD is a 26 amino acid sequence in a helical form that is responsible for anchorage 
of the ligand to the cellular membrane. The ICD is composed by 126 amino acid residues (Li, 
2014; Grochowski et al , 2016).  
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Figure 1.10. Human JAG1 Stuctrure. JAG1 is a type I transmembrane protein with an extracellular region 
containing 16 EGF repeats. The DSL domain that is located in the N-terminal region is reponsible for the 
binding to Notch receptors and the CD46 protein. A C2 domain at the very N-terminus reduces Notch 
activation upon binding to phospholipid bilayers. JAG1 can be cleaved by ADAM17 metalloprotease to 
release soluble protein that mediates paracrine Notch signaling on neighboring cells. It can also be 
processed intramembranously by γ-secretase to release the intracellular domain that contains a PDZ motifi 
responsible for the intrinsic reverse signaling induced by JAG1 (Li, 2014). 
JAG1 is expressed throughout the human body at different levels, depending on the 
developmental phase and tissue. Heart, placenta, pancreas, and prostate have high JAG1 
expressing levels, whereas lung, liver, kidney, thymus, testis, and leukocytes present low 
expressing levels (Jones et al, 2000; Gasperowicz et al., 2008; Grochowski, et al, 2016). 
Glycosylation of the Notch receptors highly influences the binding and activating capacity of 
JAG1 (Benedito et al., 2009; Rana et al., 2012; Li, 2014). Importantly, soluble JAG1 ECD has 
been shown to promote Notch signaling activity between endothelial cells and tumor cells, 
allowing the activation of the pathway in more distant cells. This means that JAG1 mediates the 
paracrine activation of the Notch pathway (Li, 2014). 
 
1.3.1 JAG1 and Cancer 
The involvement of JAG1 in cancer was initially discovered in 2005 with a study that 
correlated BC survival with JAG1 expression levels (Reedijk et al., 2005; Grochowski et al , 
2016). Since then, JAG1 has been shown to be overexpressed in many types of cancers, such 
as TNBC, pancreatic, gastric, colorectal, cervical, ovarian, brain, and lung, and associated with 
tumor aggressiveness and decreased overall survival. JAG1 overexpression contributes to 
tumor growth, metastasis, recurrence and drug resistance, by acting directly on cancer cells and 
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modulating the tumor microenvironment. JAG1 promotes cancer cell survival, proliferation, 
migration, invasion, and metastasis. In the tumor microenvironment, JAG1 promotes tumor-
associated angiogenesis and inhibits the immune responses against cancer cells by inducing 
regulatory T cells through modulation of various cytokines, and growth factors (Choi et al., 2008; 
Lu et al., 2013; Xing et al., 2013; Li, 2014; Grochowski et al., 2016).  
Importantly, JAG1 has been shown to contribute to patient relapse, cancer metastasis 
and increased invasive potential, and resistance to several cancer drugs through its ability to 
promote the maintenance and expansion of CSCs (Creighton et al., 2009; Singh et al., 2010; Li, 
2014). For instance, an in vitro study in BC demonstrated that the promotion of CSC-renewal is 
due to high expressing levels of JAG1 (Sansone et al., 2007; Li, 2014). Other studies showed 
that JAG1 is the main ligand driving Notch signaling-mediated CSCs maintenance.  
Epithelial-mesenchymal transition (EMT) confers to the tumor cells the invasion and 
metastasis properties to invade the surrounding tissues and to colonize distant organs (Li, 
2014). Several studies demonstrated the involvement of JAG1 in the EMT process in various 
cancers (Leong et al., 2007; Li, 2014). Studies in BC have shown that JAG1 is responsible for 
the dissemination of cancer cells to the bones and brain (Sethi et al., 2011; Xing et al., 2013). 
Notably, other cancer related pathways such as TGF-β, WNT/β-catenin, IL-6, and NF-
кB can induce the expression of JAG1 to potentiate their oncogenic effects (Zavadil et al., 2004; 
Sansone et al., 2007; Rodilla et al., 2009; Chen, et al , 2010; Li, 2014). 
Considering the major effects of JAG1 in various aspects of tumor biology, JAG1 has 
emerged as a particularly attractive therapeutic target in various types of aggressive and/or 
metastatic cancer, Including TNBC (Li, 2014). 
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Figure 1.11. JAG1 effects in cancer. JAG1 induces tumor cell growth and inhibits their apoptosis, 
contributes to cancer stem cell population maintenance, and enhances cancer metastasis by inducing 
EMT. In the tumor microenvironment, JAG1 promotes tumor-associated angiogenesis, and inhibits tumor-
specific immunity by inducing regulatory T cells (Li, 2014). 
 
1.4 Antibodies 
Antibodies (Ab) are soluble glycoproteins belonging to the immunoglobulin (Ig) family 
(Lòpez-Ribot et al., 2007; Schroeder et al , 2013). They are produced by plasma cells and they 
are found in the peripheral blood and external body fluids (Lòpez-Ribot et al., 2007). Antibodies 
have several functions: to neutralize viruses and identify and mark microbes and 
foreign/abnormal antigens for destruction (Lòpez-Ribot et al., 2007). Antibody-based therapy is 
now one of the most successful and important strategies for treating patients with many 
immune-mediated diseases and hematologic and solid tumors (Scott et al., 2012; Ecker et al., 
2015). 
 
1.4.1 Antibodies Structure 
The antibodies structure consists of two identical copies of a heavy chain (HC) and two 
identical copies of a light chain (LC) in a Y-shaped structure. Each HC has approximately 50 
kDa (450 amino acid residues) and each LC 25 kDa (212 amino acid residues) (Lòpez-Ribot et 
al., 2007; Schroeder et al, 2013). The heavy and light chains are linked by disulfide bonds 
(Williams et al, 1988; Schroeder et al, 2013). The N-terminal region of the Ab is characterized 
by sequence variability regions in both heavy (VH) and light (VL) chains (Lòpez-Ribot et al., 
2007).  
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The Ab also contains a hinge region between the CH1 and the CH2 that confers flexibility 
to the two antigen-binding sites to operate independently, which is important due to the space 
between the protein molecules or the microbes (Lòpez-Ribot et al., 2007). The remaining Ab 
sequence is relatively constant either in the LC (CL) or in the HC (CH1, CH2, and CH3 regions).  
Antibodies can also be divided into three fragments: two fragment antigen-binding (Fab) and a 
fraction crystallized (Fc). The Fab fragment is constituted by the VL, CL, VH, and CH1 regions, 
and is responsible for the binding to the antigen. The Fc fragment contains the CH2 and CH3 
regions and provides a binding site to immunocompetent cells receptors (Lòpez-Ribot et al., 
2007).  
There are five different Ig classes (isotypes) of Ab molecules based on the number of Y 
units and the structure of its carboxy (C)-terminal part on the HC. The five classes of Igs are: 
IgG, IgM, IgA, IgE and IgD. They differ in their biological properties, functional locations and 
ability to react with different antigens (Goldsby et al., 2003; Murphy, 2012). 
There are two types of LC, the lambda (λ) and kappa (κ), based on small differences in the 
polypetide sequence. However, each class can have either a λ or κ LC and no functional 
differences have been found between them (Schroeder et al, 2013).  
The Ab binding capacity is influenced by its affinity and avidity to the antigen. Affinity is 
the strength of the interaction between the Ab and the antigen. Therefore, high affinity means 
stronger connections to the antigen at a lower Ab concentration. Avidity is the combined 
strength of multiple interactions between the Ab and the antigen epitopes. It is dependent on the 
number of epitopes and number of antibody-combining sites (Lòpez-Ribot et al., 2007). 
 
 
Figure 1.12. Schematic diagram of Ig structure. The Ab is constituted by two light chains and two heavy 
chains each organized in variable  regions (VH, VL) and constant regions (CH1, CH2, CH3, CL) linked 
together by disulfide bonds. In the centre of the molecule there is the hinge region, represented here as 
“papain cleavage site”. Papain is an enzyme that digests the molecule and divides it into three - two Fab 
fragments and one Fc fragment. Rose and red – light chains and Blue – heavy chains (Legninger, 5th 
edition). 
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The Ab specificity is determined by the variable regions (VL and VH). These regions 
contain amino acid sequences that create a three-dimensional structure specific for each 
antigen. These sequences are called complementary-determining regions (CDRs), and each 
chain contains three CDRs (CDR1, CDR2, CDR3) (Lòpez-Ribot et al., 2007). The CDRs in the 
HC correspond to the amino acid residues 30 to 36, 49 to 65 and 95 to 103, while in the LC 
correspond to the amino acids 28 to 35, 49 to 59 and 92 to 103 (Murphy, 2011). The rest of the 
variable domain has a more constant sequence termed the framework regions (FR). There are 
four frameworks, FR1, FR2, FR3, and FR4, responsible for the CDRs positioning on the surface 
of the chain creating a hypervariable region at the end of each Ab (Murphy, 2011). CDRs amino 
acid sequences determine the shape and ionic properties of the antigen-binding site, 
determining the specificity of the Ab (Murphy, 2011).  
The Ab diversity is generated by somatic recombination in B lymphocytes, where the 
variable gene segments are linked to other gene segments. LC contains VL, JL, and CL gene 
segments and the HC contains VH, DH, JH, and CH gene segments (Figure 1.13). CL gene 
segments encode the constant regions (Goldsby et al, 2003). In the assembled LC variable 
domain, the VL gene segment encodes FR1 to 3, CDR1 and 2, and two thirds of CDR3, while 
JL encodes the rest of CDR3 and FR4. In the HC variable domain, VH gene segment encodes 
FR1 to 3, CDR1 and 2 and JH encode FR4. The CDR3 is generated in developing B cells by 
the joining process, containing the entire DH as well as portions of VH and JH gene segments 
(Paul, 2013).  
 
 
Figure 1.13. Representation of the chromosomal organization of the Ig heavy and light gene 
clusters. Genes of the heavy chain variable region are divided into the VH, DH and JH gene regions. The 
genes in the light chain variable region are divided into the VL and the JL gene regions (adapted from 
https://www.kyowakirin.com/antibody/basics/diversity.html). 
Being the Ab glycoproteins, they suffer glycosylation as modifications. Glycosylation 
alters the charge profile of the Ab and can affect its stability and potency (Mo et al., 2018). 
Usually, an Ab is glycosylated in the Fc domain with an N-linked glycosylation on Asn297 on 
each of the two CH2 domains that have been shown to have little impact on Fc functions. 
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However, the CDRs are unique to each Ab and glycosylation in the CDRs may affect antigen 
binding (Mo et al., 2018). Variation in glycosylation is observed between Ab molecules as well 
as within the two chains on the same molecule due to differences in terminal sialic acid, 
galactose, N-acetyl glucosamine, and fucosylation of the core. The glycans on the CH2 interact 
with a hydrophobic pocket on the Fc domain that stabilizes the Ab structure (Liu et al., 2006; 
Sibéril et al., 2006; Schroeder et al, 2013). 
 
1.4.2 Monoclonal Antibodies 
Monoclonal antibodies (mAb) are monospecific Ab produced from identical immune 
cells that derive from a single clone, and are specific for a unique epitope (Xin et al, 2013). 
mAbs are now being used to treat many diseases, such as cancer, infectious diseases, allergy, 
asthma, and some autoimmune diseases, where they can neutralize substances, block 
receptors, bind to cells and modulate the host immune system (Schirrmann et al, 2011). 
Trastuzumab and pertuzumab are two examples of therapeutic mAbs used for the treatment of 
patients with HER2-overexpressing metastatic BC (Gianni et al., 2012; Lamy et al., 2017). The 
use of mAbs as therapeutic agents against Notch in recent years resulted in anti-tumor activity 
in different types of cancer, with the advantage of overcoming the gastrointestinal toxicities 
associated with GSIs (Wu et al., 2010; Sharma et al., 2012, 2013; Lamy et al., 2017). Different 
therapeutic approaches have been followed to develop mAbs towards various Notch signaling 
proteins. Some consists in targeting the receptor-ligand binding domain while others in blocking 
the intracellular Notch cleavage by γ-secretase enzyme through specific binding to the NRR 
(Wu et al., 2010; Sharma et al., 2012, 2013; Lamy et al., 2017). OncoMed Pharmaceuticals 
developed two therapeutic mAbs: bronticuzumab, targeting Notch1 receptor (Davis et al., 2013) 
and tarextumab, targeting both Notch2 and 3 receptors (Yen et al., 2015), to increase the 
efficacy of conventional BC therapies (Lamy et al., 2017). Bronticuzumab showed clinical 
benefits in phase I studies in patients with advanced solid tumors, in a patient with refractory 
HER2-negative BC and reduced the number of circulating tumor cells in a patient with colorectal 
cancer (Davis et al., 2013; Lamy et al., 2017). Tarextumab showed in a phase I study in patients 
with advanced solid tumors, to prolong stable disease in TNBC, sarcomas, and rectal cancer 
(Davis et al., 2013; Lamy et al., 2017). In both studies, small toxicity levels were obtained. 
 
1.4.2.1 Antibody Formats 
The antigen-binding fragments can be produced by biochemical digestion and include 
Fab, (Fab')2, and FV. The Fab fragment is composed of the LC and the variable domain and 
CH1 from the HC, thus containing one antigen-binding site (Frenzel et al., 2013). Divalent 
(Fab')2 fragments have two antigen-binding regions, linked by disulfide bonds, and are 
produced by pepsin digestion of IgG or IgM Abs, which retains a portion of the hinge region. 
The Fv fragment is the smallest antigen-binding fragment and consists of one variable domain 
of the HC. The Fv fragments have low stability so single-chain Fv fragments (scFv) were 
developed, in which one variable region of each light and heavy chain are tethered together by 
a soluble linker, for stabilization of the molecule. scFvs are produced using genetic engineering 
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methods. scFv fragments have a complete binding site of an Ab and they are presently the most 
popular format, as the Fab, of recombinant Abs with wide application in healthcare and 
biotechnology (Frenzel et al., 2013). Evolution of this platform has also resulted in bi-scFvs, 
using a linker with 3-11 residues long, and in bispecific antibodies that can cross-link different 
antigens and thus hold promise as anti-cancer drugs. In addition to conventional Abs, camelid 
species contain a subset of HC Abs (hcAb) exclusively composed by HC homodimers lacking 
light chains. The Fab portions of these antibodies, called VHH, are the smallest antigen-binding 
regions naturally found. They are stable and can be easily produced in huge quantity by using 
common simple protein expression systems (Muyldermans, 2013). 
 
 
Figure 1.14. Different Ab formats. Representation of several Ab formats, including the intact IgG Ab 
alongside various representations of Ab fragments. Image from https://www.antibodies-
online.com/resources/18/1502/antibody-and-immunoglobulin-alternatives-part-1/).  
 
1.5 Phage Display 
The phage display technology was presented by George Smith in 1985. In his work he 
demonstrated that foreign DNA fragments could be fused to a coat protein-coding gene of 
filamentous phages and expressed as a fusion proteins on the surface of phages, leaving these 
intact and operational (Ahmad et al., 2012; Smith and Petrenko, 1997). McCafferty proved that 
cloned Ab fragments could be similarly displayed on phage particles as functional proteins, and 
after that, the first libraries of phages were generated (Ahmad et al., 2012;).  
The main purpose of this technique is the selection of peptides or proteins capable of 
binding with high affinity to a specific target, using the phage libraries, for drug and vaccine 
discovery and development (Dantas-Barbosa et al, 2012; Ahmad et al., 2012;). The phage 
libraries are usually constructed by mass cloning of a pool of genes encoding millions of 
variants of ligands into a vector, allowing the effortless construction of highly diverse collections 
(Hoogenboom et al., 1998). Upon expression, the protein fusion will be incorporated into new 
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phage particles that are assembled in the bacterium and the fusion product is then displayed on 
the phage surface (Hoogenboom et al., 1998)(Figure 1.15). 
  
 
Figure 1.15. Phage Structure. Generic schematic representation of a protein-displaying phage particle. In 
the phage genome represented in blue is the coat protein gene and in black is the protein of interest gene. 
 
The Phage Display technology is based on the fact that phage phenotype and genotype 
are physically linked. This allows the enrichment of the selected phage and also further 
manipulation and development of genetic and biochemical studies of the correspondent 
displayed proteins (Cabral, 2014; Hammers et al., 2014). 
E.coli is the bacteria host normally used in phage display to display scFv and Fabs 
fragments (Hoet et al., 2005; Schirrmann et al., 2011).  
Two different genetic systems have been developed for the expression of the proteins. 
One inserts directly the Ab genes into the phage genome fused to the wild-type M13 phage 
protein III gene (McCafferty et al., 1990; Schirrmann et al., 2011). The second and more used 
uncouples the Ab expression from phage propagation by providing the genes encoding the Ab: 
pIII fusion proteins on a phagemid in a separate plasmid. This phagemid contains a phage 
morphogenetic signal for packaging the vector into the assembled phage particles. This makes 
the Ab gene replication and expression uncoupled from the phage replication cycle, leading to 
higher genetic stability and a simplification of the Ab gene library amplification. For the 
production of Ab phage particles, a helper phage is necessary for supplying all structural 
proteins (Breitling et al., 1991; Hoogenboom et al., 1998; Schirrmann et al., 2011).  
Phage display is a robust and versatile technique that can be easily implemented and 
operated (Dantas-Barbosa et al; 2012; Hoogenboom et al., 1998). It can be used for a variety of 
objectives, such as the identification of cell/tissue or disease-specific biomarkers, protein-
protein interactions, receptor-ligand characterization, epitope mapping, gene delivery, and 
proteomic, functional genomic approaches and in the development of mAbs that can bind to a 
target of interest with high affinity (Frenzel et al., 2017). 
 
1.5.1 Types of Phage Display Libraries 
Phage Display antibody libraries are composed by the genomic information coding for 
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Ab variable domains, which can be derived from B cells of immune or naïve donors. These 
libraries usually display Ab fragments - Fab or scFv, since complete IgG molecules cannot be 
displayed on the phage surface due to steric hindrance. However, those Ab fragments selected 
by phage display can be then reformatted into complete IgG molecules and further be used in 
diagnosis, research and/or therapeutics (Silverman;, 2001; Hammers et al., 2014; Groff et al., 
2015). 
Based on the source of Ab genes used for their construction, the libraries can be divided into 
four categories: immune, naïve, semi-synthetic, and synthetic libraries (Rami et al., 2017). 
Immune libraries are constructed from B cells isolated from the spleen of immunized animals, 
previously infected with a specific antigen (Schirrmann et al., 2011; Rami et al., 2017). These 
libraries not only have the advantage that the V-genes contain hypermutations but also have the 
added feature that they are affinity matured inside the animals. As such, immune libraries are 
useful for analyzing natural humoral responses or to study in vitro immunization procedures. 
However, they present some disadvantages: i.e. each library is specific towards a unique 
antigen, there can be ethical issues due to the use of animals, and there is a high cost in their 
generation (Hoogenboom et al., 1998; Schirrmann et al., 2011; Rami et al., 2017). 
The naive, semi-synthetic and synthetic libraries can be grouped as “single-pot” 
libraries, because they are designed to create a variety of Ab fragments capable of binding to 
every existing antigen, which makes them very useful for the selection of human Abs 
(Hoogenboom et al., 1998; Schirrmann et al., 2011) .  
Naive libraries are made from a primary Ab repertoire that contains a large amount of 
IgM Abs capable of recognizing many different antigens. These IgMs are cloned as a naive 
repertoire of rearranged genes, by harvesting the V-genes from the IgM mRNA of B-cells of 
non-immunized human donors. The V-genes are consequently amplified from B-cell cDNA 
using family-based oligonucleotides, and the heavy and light chains are randomly combined 
and cloned to encode a library of scFv or Fab Ab fragments. These libraries can generate Ab to 
a large panel of antigens, including self, non-immunogenic and relatively toxic antigens 
(Hoogenboom et al., 1998). The affinity of the selected Abs from a naïve library is proportional 
to the size of the library, which contains a great number of phage particles, from which each one 
encodes and displays different molecules, usually 106–1011 different ligands in a population of at 
least 1012 phage molecules (Hoogenboom et al., 1998; Bazan et al., 2012). 
Semi-synthetic libraries are constructed from unrearranged V genes from germline B 
cells or from one Ab framework in which one or several CDRs are randomized by PCR or 
oligonucleotide direct mutagenesis, usually within the CDR3 regions. This combination of 
natural and synthetic diversity increases natural diversity (Schirrmann et al., 2011; Cabral, 
2014).   
Synthetic libraries are generated in vitro by the assembly of V-gene segments from 
human frameworks with randomized CDR cassettes (Hoogenboom et al., 1998; Schirrmann et 
al., 2011). The CDR3 from the heavy chain has the most structural and sequence diversity, 
while the remaining CDRs have limited variation (Hoogenboom et al., 1998). These libraries 
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allow control over the genetic characteristics of V genes and the introduction of diversity 
(Silverman;, 2001).  
 
 
1.5.1.1 Tomlinson Human Single Fold scFv libraries I + J 
The phage display antibody libraries used for this work were the Tomlinson Human 
Single Fold scFv libraries I + J (reIn_0017). These synthetic libraries are composed of over 100 
million distinct scFv fragments cloned in the ampicillin resistant phagemid vector pIT2 in fusion 
with the C-terminal region of the phage coat protein pIII (Figure 1.16). The scFv fragments are 
composed by a single human polypeptide comprising the VH and Vк (HC and LC, respectively) 
domains attached to one another by a flexible Glycine-Serine linker. In addition, the scFv carries 
two peptide tags: a His-tag that facilitates purification, and a myc-tag that allows evaluation of 
the scFv expression/display using an anti-c-Myc Ab. The pIT2 plasmid contains two replication 
origins: colE1 ori for plasmid amplification in the bacterial cells, and the M13 ori for the 
amplification of the plasmid in the phages. The plasmid also contains a lacZ promoter and a 
pelB leader sequence to drive and direct the expression of the scFv, respectively (Figure 1.16). 
Both libraries are based on a single human framework for VH (V3-23/DP-47 and JH4b) and Vк 
(O12/O2/DPK9 and Jк1) with diversified (DVT) side chains incorporated in the antigen binding 
sites. The Tomlinson J library also incorporates NNK side chains in the antigen binding sites. 
These libraries are highly diverse in the antigen binding site region thus allowing the generation 
of mAbs that can subsequently be reformatted into various Ab formats (Xia et al., 2013; 
Brinkmann et al., 2017). The Tomlinson Human Single Fold scFv libraries I + J have been 
previously successfully used in our laboratory for the selection of specific antibodies against the 
DLL1 Notch ligand (manuscript in preparation for publication). 
 
Figure 1.16. Vector map of pIT2 vector from the Tomlinson Human Single Fold scFv libraries I + J 
1.5.2 Phage Display Panning 
“Panning” is the name given to the in vitro selection process of Abs specific to an 
identified target,, based on their binding affinity that allows the rapid identification and 
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enrichment of target-specific binders from a large excess of non-binding clones (Parmley et al., 
1988; Hoogenboom et al., 1998; Schirrmann et al., 2011). This is a cyclic procedure that 
basically consists on multiple rounds of several steps: first the phage libraries displaying the Ab 
repertoire are incubated with a specific target, usually protein, and washing is performed to 
remove non-specific or low affinity phage binders. Then, elution is performed to recover the 
specifically bound phages. Finally, eluted phages are amplified for the next panning round or for 
screening (Figure 1.17)(Hoogenboom et al., 1998). A single round of selection and amplification 
can lead to an enrichment of 20 to 1000-fold of a specific phage (Wang et al., 2011). Performing 
multiple selection rounds with selected phages increases the enrichment of specific binders 
(Watkins and Ouwehand, 2000), allowing the isolation of very specific antigen-binding clones 
(Hammers and Stanley, 2014). Three panning rounds are the most usual approach, however, 
there is no round limit, and this is very much dependent on the target and on the library, but 
usually the higher the number of rounds leads to an increase in the specificity but comes with 
the disadvantage of decrease in diversity. It is also common to include in each panning round a 
depletion step, using a non-target molecule, before the selection step in order to remove non-
specific phage binders (Ferreira, 2015).  
 
 
Figure 1.17.Representation of the Phage Panning strategy for the selection of Abs. Phage pool Abs 
are selected against a target antigen, coated on a surface. The specific phages bind to the antigen and the 
non-specific are removed by washing. The selected specific phages are eluted and if need amplified for a 
subsquent round of panning (adaped from Frenzel et al., 2017). 
The success of ligand phage display relays on the combination of the display and the 
enrichment method (Hoogenboom et al., 1998). 
If the antigen is presented in a more complex environment, for example panning on 
cells, the selection procedure becomes more difficult as other antigens are  also present and 
the expression levels of our target may be low, requiring more rounds of panning and more 
sophisticated protocols (Dantas-Barbosa et al., 2012; Hammers et al., 2014). 
After panning, the specific antigen-binding phages, or the corresponding soluble Ab 
fragments, are analyzed by ELISA assays towards the target antigen. The individual binders 
that specifically recognize the antigen by ELISA are selected and their DNA isolated and 
sequenced to identify the unique clones. Those unique clones can be then reformatted into IgG 
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(or other Ab formats, depending on their purpose) and further biochemically characterized 
(Winter et al, 1991; Schirrmann et al., 2011). 
 
1.6 Aim 
The main objective of this thesis was to develop specific anti-JAG1 Abs for BC 
therapies using phage display technology. The main tasks of this thesis are: 
1.  Selection of JAG1 specific Abs by phage display technology using the 
commercial Tomlinson Human scFv libraries I+J and recombinant JAG1 proteins 
as antigens; 
2.  Evaluation of the binding properties of selected unique scFv JAG1 Ab fragments 
to recombinant JAG1 proteins by ELISA; 
3.   Assessment of the epitope of the best anti-JAG1 scFv binders using different 
peptides of conserved JAG1 regions.  
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2. Materials and Methods  
 
2.1 Mammalian cell Culture  
Human breast cancer cell lines MCF-7 (ATCC HTB-22) and MDA-MB-231 (ATCC HTB-
26) were cultured in high glucose, pyruvate DMEM medium (#41966) supplemented with 10% 
heat-inactivated fetal bovine serum (FBS), 100μg/mL penicillin and streptomycin (#15140-122), 
and 0.1mM non-essential amino acids (#11140-035), in the case of MCF-7 cells. Media and 
reagents were purchased from Gibco. Cells were incubated at 37˚C in a humidified atmosphere 
and 5% CO2. Culture media was replaced every 2–3 days. 
 
2.2 Bacterial cell culture and glycerol stock preparation 
The Escherichia coli (E. coli) strain used was: TG1 (Lucigen) - F' [traD36 proAB+ lacIq 
lacZΔM15] supE thi-1Δ(lac-proAB) Δ(mcrB-hsdSM)5 (rK-mK). The helper phage used for phage 
display was M13KO7 (InvitrogenTM). 
Initially the E. coli was grown in plates containing minimal media, composed by 1% 
glucose; 2mM of MgSO4; 0.1mM of CaCl2; 0.005 % thionine; 15g/L of agar and 1x M9 minimal 
salts (Sigma-Aldrich, M6030), during 48 hours at 37°C. For the panning assays, and the 
amplification of selected clones (described below), a sample of the bacteria grown in minimal 
media was scraped from the plates, and cultured in 5mL of 2x Yeast Extract Tryptone (2YT) 
medium (16g/L of Tryptone, 10g/L of Yeast Extract and 5g/L of NaCl) with 1% glucose, in 50mL 
falcon tubes overnight (O/N) at 37°C and 250 rpm. 
Bacteria infected with the phage output pools from each round of selection were plated 
in 2YT agar plates (2YT medium with 15g/L of agar) with 1% of glucose and 10 µg/mL ampicillin, 
and incubated O/N at 37°C. For the bacterial glycerol stocks, the bacteria on the plates were 
scraped using 5-10mL of 2YT medium containing 15% of glycerol (VWR Chemicals, 
#24385.295), centrifuged (Eppendorf, centrifuge 5810R) at 3220 xg for 20 minutes at RT. The 
supernatant was discarded, and the resulting bacterial cells were resuspended in 3mL of 2YT 
with 15% of glycerol, aliquoted in cryovials, and frozen at -80ºC.  
 
2.3 Bacteria Growth Curve  
TG1 cells were grown O/N in 2YT medium supplemented with 1% of glucose and 
incubated at 37ºC and 250 rpm. After this, two pre-inoculums were prepared, where 5L of the 
O/N culture was added into 96-well suspension culture plates, previously filled with 100µL/well 
of fresh 2YT medium with 1% of glucose. In parallel the necessary amount of the O/N culture 
was diluted in 5mL of fresh 2YT medium with 1% of glucose in order to obtain an OD600nm of 
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0.05.  
In the next day, two inoculums were prepared, one in 96-well suspension culture plates 
and the other in 50mL falcon tubes, prepared with fresh 2YT medium with 1% of glucose 
(100l/well of 96-well plate and 10 mL/50 mL falcon tubes), in order to obtain an OD600nm 
between 0.05 and 0.1. Monitoring of the OD600 at several time points was performed through the 
experiment. The growth curves were determined by plotting the optical densities (OD600nm) of 
bacterial suspensions at the different times for each tested condition.  
 
2.4 Phage Display 
2.4.1 Panning  
The panning strategy consisted in three rounds of selection, using the Tomlinson 
Human Single Fold scFv Libraries I + J or the Tomlinson I alone and the JAG1-EGF3-Fc 
recombinant protein as antigen, preceded by a depletion step with an Fc control protein 
(corresponding to the Fc portion of the antigen). 
The recombinant JAG1-Fc fused proteins and the Fc control protein were previously 
generated in the laboratory using the JAG1 cDNA (Sino Biological, HG11648-M) and the 
pFUSE-IgG1-Fc vector (InvivoGen, pfuse-hg1fc1) basically as described in (Sales-Dias et al, 
2019). 
Pannings were performed using immunotubes (Maxisorp Startube, Thermo Scientific, 
75X12 NUNC-IMMUNO) pre-coated O/N at 4ºC with 25µg/mL (for the first and second rounds) 
or 12.5µg/mL (for the third round) of an anti-human IgG (Fc specific) antibody (Sigma, I2136) in 
a final volume of 4mL of PBS. On the next day, the immunotubes were washed three times with 
PBS and coated with 25µg/mL of JAG1-EGF3-Fc protein (target) or the Fc control protein 
(depletion) in a final volume of 4mL of PBS for one hour at RT with gentle shaking (Stuart 
rotator, SB3). After this incubation step, the immunotubes were washed three times with PBS 
0.05% Tween (Sigma-Aldrich, P7949)(PBST/0.05%) and blocked with 1mL of 2% skim milk 
(Nestlé Molico, #5601001135309) in PBS for two hours at RT with gentle shaking. After two 
hours, the immunotubes were washed three times with PBST/0.05%. 
For the 1st round of the panning, the Human Single Fold scFv libraries I and J were 
mixed in a final volume of 1mL at a concentration of 1.4x1013 and 1.7x1013 cfu’s/mL, 
respectively, to a final concentration of 3.1x1013 cfu’s/mL. When using the library I individually, 
the final concentration of the library was 1.84x1013 cfu’s/mL. The phages were precipitated 
using 250µL of PEG-NaCl (Sigma-Aldrich, #81260) for one hour on ice. After the precipitation 
step, the phage libraries were centrifuged (Eppendorf, centrifuge 5417R) at 14000 xg for 10 
minutes at 4°C. The supernatant was discarded and the resulting pellet containing the phages 
was resuspended and blocked in 1mL of 2% skim milk in PBS for 30 minutes at RT with gentle 
shaking.  
Precipitated and blocked phages were then added to the depletion immunotube (coated 
with the control Fc control protein) and incubated for 30 minutes at RT with gentle shaking – 
depletion step. After incubation, the depleted phages were transferred to the target immunotube 
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(coated with the JAG1-EGF3-Fc protein) and incubated 1 hour at RT with gentle shaking, for the 
selection of specific JAG1-EGF3 binders. After incubation, the supernatant was discarded and 
the immunotube was washed five times with 4mL of 2% milk with PBST/0.05%, followed by five 
times with 4 mL of PBST/0.05%, and once with 4mL PBS. Thereafter, the phages were eluted 
from the immunotubes by incubating for 8 minutes at RT with gentle shaking with a solution 
containing 67mM TEA (Fluka Analytical, #990279) in 300µL of PBS. The supernatant with the 
eluted phages was neutralized with 625mM Tris-HCl (Invitrogen, #15567-817) and mixed by 
inversion and kept on ice. The solution was then transferred to an Eppendorf tube.  
 
2.4.2 Phage Amplification in E. coli TG-1 cells 
To proceed between rounds, previously grown TG1 E. coli cells pre-inoculated into 5mL 
of 2YT medium as described above were diluted in 30mL of 2YT medium with 1% of glucose in 
a 250mL Erlenmeyer flask in order to obtain an OD600nm of 0.05 and incubated at 37°C and 250 
rpm. When the inoculum reached an OD600nm of 0.4-0.5, 3.75mL of the inoculum was mixed with 
3mL of 2YT medium and 750µL of the eluted phages from each selection round. This mix was 
incubated for 30 minutes at 37°C. After incubation the mix was centrifuged for 10 minutes at 
3220 xg at RT, and the supernatant was discarded. Cells were resuspended in 1mL of 2YT 
medium with 1% glucose. Then 300µL from mix were used for the glycerol stocks (prepared as 
described above) and the other 700µL of the cell’s solution were added to 10mL of 2YT medium 
with 1% of glucose and 100µg/mL ampicillin (Sodium Salt, BioChemica, A0839). The cells were 
then infected with helper phage M13K07 (5x1010 cfu’s/mL). The culture was incubated for 30 
minutes at 37°C. The incubation was followed by a centrifugation for 10 minutes at 4°C and 
3000g. After, the pellet was resuspended in 50mL of 2YT with 0.1% of glucose, ampicillin 
(100µg/mL) and kanamycin (Disulfate Salt, Sigma Aldrich, K1876, 50µg/mL), and incubated O/N 
at 30°C and 250 rpm. 
In the next day, the bacteria culture was centrifuged at 3220 xg for 30 minutes at 4°C. 
10mL of PEG/NaCl was added to 40mL of the supernatant and incubated on ice for 1 hour. 
After that, the culture was centrifuged at 3220 xg for 30 minutes at 4°C. The supernatant was 
discarded, and the pellet was re-centrifuged at 3220 xg for 2 minutes at 4°C for the removal of 
the remaining supernatant. The pellet containing the phages was resuspended in 1mL of PBS, 
transferred to Eppendorf tubes, and centrifuged at 11600 xg for 10 minutes at RT. The 
supernatant was then transferred to a new tube for the next panning rounds.  
 
2.4.3 Titration of phage inputs and phage outputs from the 
panning strategy 
Inputs and outputs from the panning were evaluated by titration of the phages. For that, 
10µL from the pool phages, before depletion (Input 1), after depletion (Input 2), and after 
selection (Output) were collected into different Eppendorf tubes. Serial dilutions of the inputs 
and outputs were prepared until dilution 10-12 and 10-7, respectively, using 90µL of 2YT medium 
with 1% of glucose and ampicillin (100µg/mL). 10µL of each phage dilution was mixed with 
50µL of E. coli (TG1) at OD600nm of 0.4-0.5 along with 40µL of 2YT with 1% of glucose. After 
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incubation at 37°C for 30 minutes, dilutions 10-8 to 10-12 of the inputs and 10-4 to 10-7 of the 
outputs were plated in 2YT with 1% of glucose and ampicillin (100µg/mL) agar plates. Non-
infected E. coli TG1 cells at OD600nm of 0.4-0.5 were also plated in 2YT with 1% of glucose and 
ampicillin (100µg/mL) agar plates as well as in in 2YT with 1% of glucose and kanamycin 
(50µg/mL) agar plates as controls to check phage contamination. Plates were incubated O/N at 
37°C. The number of colonies for each dilution was counted, and the number of colony forming 
units (cfu)/mL calculated according to the Formula 2.1. The percentage of phage recovery was 
also calculated following Formula 2.2 and the enrichment between rounds following Formula 
2.3. 
 
 
Formula 2.1. Colony forming units (cfu) per mL calculation from colonies counted on plates. 
 
 
 
Formula 2.2. Percentage of phage recovery in a determined round of selection. 
 
 
 
Formula 2.3. Enrichment increase in recovered phages in a determined round of selection relatively 
to the previous round. 
 
 
2.5 ELISA 
2.5.1 scFv-on-phage ELISA  
E. coli TG1 bacteria colonies that were infected with phage pools from the output of 
panning rounds 2 and 3, were randomly picked with a toothpick and incubated in 150µL/well of 
2YT media supplemented with 1% of glucose and ampicillin (100µg/mL) in a 96 well culture 
plate (greiner bio-one, #655185). The plates were incubated O/N at 37°C at 180 rpm. Then, 5µL 
of the O/N culture were diluted in 100µL of 2YT medium with 1% of glucose and ampicillin 
(100µg/mL) and incubated at 37°C and 180 rpm. After 2 hours and 30 minutes, when the culture 
reached an OD600nm between 0.4 and 0.5, each well was infected with 109 cfu’s of M13K07 
helper phage and incubated for 1 hour at 37°C at 30 rpm. Then, the plate was centrifuged for 10 
minutes at 1800 xg and 4°C, the pellets were resuspended with 200µL/well of 2YT media 
supplemented with 0.1% of glucose, ampicillin (100µg/mL) and kanamycin (50µg/mL), and 
incubated O/N at 30°C and 180 rpm. 
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96 wells Maxisorp plates (Thermo Scientific, #44-2404-21) were coated with 5µg/mL of 
JAG1-EGF3-Fc or control Fc proteins or anti-c-Myc antibody (Roche, #11667203001) and 
incubated O/N at 4°C. A non-coated Maxisorp plate was used as a negative control for ELISA. 
 After coating, the plates were washed 3X with 200µL/well of PBS and blocked for 1 
hour at RT with 200µL/well of 2% milk in PBS. The plates were washed 3X with PBS, 50µL/well 
of phages were added to each well and the plates were incubated for 1 hour at RT.  
After incubation with the phages, the plates were washed 3X with PBST/0.05% and 
100µL of the secondary anti-M13-HRP antibody (Sino Biological, #11973-MM05T-H) diluted 
1:5000 in PBS was added to each well. The plates were incubated for 1 hour at RT. After 
incubation the plates were washed 3X with PBST/0.05% and 50µL of the colorimetric substrate 
for horseradish peroxidase, 3,3’,5,5’-tetramethylbenzidine (Life Technologies, #002023) were 
added to each well, in the dark, until negative controls began to react, between 5 to 10 minutes. 
50µL of sulfuric acid (H2SO4) (VWR chemicals, #30149.291, 1M) were added to each well to 
stop the reaction. Absorbance was measured at 450nm in a MultiskanTM FC (Thermo Scientific). 
  
2.5.2 Epitope mapping 
In order to evaluate the specificity of the selected scFv to the different epitopes from the 
JAG1 protein, an ELISA assay similar to the one described in the section 2.5.1 was conducted. 
The differences in this protocol were on the ELISA plates used, because the peptides tested 
were biotinylated so were coated on Streptavidin Plates (Greiner Bio-One, #655990) at 1g/mL 
in PBS. 
Proteins tested were: recombinant Fc, JAG1-EGF3-Fc, JAG1-ECD-Fc, DLL1-EGF3-Fc, 
DLL1-ECD-Fc, anti-c-Myc Ab. Peptides tested were: JAG1-DSL, JAG1-EGF1, JAG2-DSL, 
JAG2-EGF1, DLL1-DSL, DLL1-EGF1, non-specific peptide.  
Peptides were diluted in two different solutions. In one solution, the peptides were used 
in their native conformation, and in the other they were linearized with 5mM 1,4-Dithiothreitol 
(DTT)(Sigma Aldrich, D9779) for 30 minutes at 37°C.  
 
2.5.3 ELISA with full IgG’s 
In order to evaluate the binding properties of the reformatted anti-JAG1 IgGs to the 
JAG1 proteins an ELISA assay was conducted.  
96-well Maxisorp plates were coated with JAG1-EGF3-Fc, JAG1-ECD-Fc, recombinant 
Fc and a positive control protein for the secondary Ab at 5µg/mL in PBS and incubated O/N at 
4°C. After incubation, the plates were washed 3X with 200µL/well of PBS and blocked with 
200µL/well of 2% milk in PBS for 1 hour at RT. After blocking, the plates were washed 3X with 
200µL/well of PBS. 2-fold serial dilutions of anti-JAG1 IgG’s (starting from 100g/mL) were 
prepared and incubated for 1 hour at RT on the blocked 96-well maxisorp plates. After the 
incubation with the IgG’s, the plates were washed 3X with PBST/0.05%. Then, the plates were 
incubated for 1 hour at RT with 100µL/well of anti-human IgG (Fab Specific)-HRP conjugated 
antibody (Sigma Aldrich, 2.5µg/mL, A0293) in PBS for the detection of anti-JAG1 IgG´s binding. 
The rest of the procedure was performed as described in section 2.5.1 ELISA.  
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2.6 DNA Extraction 
The plasmid DNA was extracted using the NZYMiniprep kit (NZYTech, MB01001) 
according to the manufacturer protocol.  
Briefly, a single colony of each of the selected anti-JAG1 scFv clones was grown in 5mL 
of 2YT media supplemented with 1% glucose and ampicillin (100µg/mL) and incubated O/N at 
37°C and 250 rpm. After incubation, each culture was centrifuged for 5 minutes at 12000 xg. 
The supernatant was discarded, and the pellet resuspended in 250µL of the A1 buffer by 
vigorous vortex. Then, 250µL of A2 buffer was added and mixed by inverting the tube 6-8 times. 
The tube was incubated at RT for a maximum of 4 minutes before the addition 300µL of the A3 
buffer. Then, the tube was inverted 6-8 times, to mix the buffers, and centrifuged for 15 minutes 
at 12000 xg. The supernatant was loaded into a spin column inserted into a 2mL collecting tube 
and centrifuged for 1 minute at 11000 xg. The flow-through was discarded, and 500µL of the AY 
buffer was loaded into the column. The column was centrifuged for 1 minute at 12000 xg and 
the flow-through was discarded. 600µL of the A4 buffer was added to the column and another 
centrifugation step was performed for 1 minute at 12000 xg.  
The spin column was re-inserted into a new collecting tube and centrifuged for 2 
minutes at 12000 xg to remove residual washing buffers. Plasmid DNA was then eluted with 
30µL of molecular biology grade H2O, its concentration determined using a nanodrop ND-
2000C spectrophotometer and stored at -20ºC. All centrifugations were performed at RT. 
 
2.7 PCR 
In order to evaluate the integrity of the scFv DNA, a PCR was conducted. The primers 
used in this reaction were the LMB3 (forward), pHEN sequence (reverse), and the Link 
Sequence (reverse) (all obtained from Integrated DNA Technologies) - Table 2.1. Two reaction 
solutions were prepared, one with the LMB3 and pHEN primers, and the second with the LMB3 
and Link sequence primers, to ensure that the entire scFv sequence was present. The first 
reaction tube aims at the amplification of the entire DNA sequence while the second one 
amplifies a fraction of the DNA ranging from the 5´end until half of the scFv DNA fragment. PCR 
reactions containing 3% DMSO (New England BioLabs, B0515A), 15 mM dNTP’s NZY Mix 
(nzytech, MB086), 1X Phusion Buffer (Thermo Scientific, F-518), 1U Phusion Polymerase 
(Thermo Scientific, F-530S), 25 mM of each primer set, and molecular biology grade H2O were 
transferred to PCR tubes containing 2ml of DNA template (50µg/µL) or H2O (used as negative 
control). The PCR reactions were performed in a thermocycler (Bio-Rad, MyCycler) under the 
following conditions: pre-incubation at 98°C for 30 seconds, followed by 30 cycles of a 10 
seconds denaturing at 98°C, a 20 seconds annealing step at 58-65°C and an extension step of 
1 minute at 72°C, ending with a 10 minutes final extension step at 72°C. When PCR reaction 
terminated samples were kept at 4°C. The samples were analyzed by DNA electrophoresis 
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using an agarose gel (section 2.11). 
 
 
Table 2.1- Primers used to amplify scFv selected against the JAG1-EGF3-Fc protein. (F)-forward 
primer, (R)-reverse primer.  
Primer Sequence 
LMB3 5’-CAG GAA ACA GCT ATG AC-3’ (F) 
Link Sequence 5’-CGA CCC GCC ACC GCC GCT G-3’ (R) 
pHEN Sequence 5’-CTA TGC GGC CCC ATT CA-3’ (R) 
 
2.8 DNA Sequencing 
The DNA sequencing reactions were performed at GATC Biotech. The scFv DNA 
samples were extracted according to section 2.4. DNA solutions at 100ng/µL of each scFv were 
prepared in molecular biology grade water. Subsequently, 5µL of each DNA were added to 1.5 
mL Eppendorf tubes containing 5µL of LMB3, pHEN sequence, or Link sequence primers, each 
at 5µM. Reactions were sent to the GATC Biotech for sequencing. Once the results were 
available, the data was analyzed using the Chromas and Clone Manager softwares. 
 
2.9 Binding of selected anti-JAG1 scFv clones to endogenous JAG1 
protein in MDA-MB-231 and MCF-7 cells by flow cytometry 
The ability of selected anti-JAG1 scFv to bind to cellular endogenous JAG1 protein 
were evaluated by flow cytometry assays (Phage FACS) using MDA-MB-231 and MCF-7 breast 
cancer cells, which express high and low levels of JAG1, respectively (laboratory data, figure 
3.14). In these assays, the binding of the phage particles displaying the specific scFv fragments 
to cells were determined using an anti-M13 antibody. For this, in the day previously to the 
Phage FACS experiment, scFv phages were prepared as described in section 2.6. 
MCF-7 and MDA-MB-231 cells were harvested at 80-90% confluence with Trypsin-
EDTA (0.05%)(Gibco, #25300062) using the standard protocol. After harvesting, cells were 
centrifuged for 5 minutes at 300 xg and 4°C and the supernatant was discarded. The resulting 
cell pellets were resuspended in FACS buffer (composed of PBS with 3% FBS (Gibco by life 
technologies, #10500-064) 0.05% Sodium Azide (Sigma Aldrich, S2002)). Next, the cell number 
was determined with a hematocytometer and cell solutions at 1X106 cells/mL were prepared in 
FACS buffer for each cell line. Then, 100µL/well of each cell suspension were added to the 
respective 96-U-bottom plate, previously coated with 200µL/well of FACS buffer, according to 
the experimental setup (one plate for each cell type). Cells were then incubated for 30 minutes 
at RT for antigen blocking. Meanwhile, the plates with the scFv clones, that grew O/N at 37°C 
as described above, were centrifuged for 20 minutes at 2000 xg at 4°C to discard bacteria slurry 
and the resulting supernatant was collected to a 96-well polypropylene deep well plate natural 
RNase/DNase-free (1mL)(Thermo Scientific-Nunc, #260252). After the incubation period, cells 
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were centrifuged for 5 minutes at 300 xg and 4°C, the supernatant was discarded by swinging 
out the plate by hand, and the cell pellets were resuspended in 50µL of the scFv supernatant, 
according to the experimental setup. In the non-stained and secondary antibody control 
conditions, cells were resuspended in 50µL of FACS buffer. Next, cells were incubated for 45 
minutes at 4°C with soft agitation in an orbital shaker. After incubation, cells were centrifuged as 
above and the supernatant was discarded. Cells were then washed 3X by resuspending the 
pellets with 200µL of FACS buffer, followed by centrifugation for 5 minutes at 300 xg and 4°C, 
with the supernatant being discarded by swinging out the plate by hand after each wash.  
After the last washing step, cells were resuspended in 100µL/well of the primary 
antibody anti-M13 Biotin at 1µg/mL (Abcam, #17269), which is specific to the gp13 phage coat 
protein. After 45 minutes of incubation at 4ºC, cells were centrifuged for 5 minutes at 300 x g 
and 4°C and the supernatants were discarded. Cells were washed 3X as previously described. 
Thereafter, cells incubated with primary antibody were resuspended in 100µL/well of the 
secondary antibody Streptavidin-Alexa-488 at 1.5µg/mL (Life Technologies, S11223) to detect 
the primary antibody. Secondary control samples (i.e. cells to which scFv clones were not 
added) were also incubated with secondary antibody alone to evaluate the unspecific binding of 
this antibody. Unstained control cells were resuspended in FACS buffer only.  
Cells were incubated for 20-30 minutes at 4°C with soft agitation and then washed 3X 
as described above. Lastly, cells were resuspended in 150µL of FACS buffer, samples were 
analyzed on a FACS Canto II Flow Cytometer and the results were evaluated with the FlowJo 
software. 
 
2.10 Evaluation of glycosylation level of anti-JAG1 IgGs by PNGase F 
assay  
To assess the glycosylation level of the IgG’s, a PNGase F assay (New England 
Biolabs, P0705S) was performed to remove the N-glycans groups under denaturing and non-
denaturing conditions according to the manufacturer’s instructions. The results were then 
evaluated by SDS-PAGE. 
 
2.10.1 Denaturing Conditions 
In brief, 5µg of each JAG1 IgG or a control glycoprotein (New England BioLabs, ref: 
#P7817S) was mixed with 1µL of Glycoprotein Denaturing Buffer (10X) (New England BioLabs, 
#B1704S) and PBS to make up a final volume of 10µL in a 1.5 mL Eppendorf tube. The proteins 
were denatured by incubating the reaction at 99°C for 10 minutes, followed by a chilling down 
on ice. After that, a spin-down was performed on the tubes. Next 2µl of GlycoBuffer 2 (10X) 
(New England BioLabs, #B3704S), 2µl of 10% NP-40 (New England BioLabs, #B2704S) and 
6µl of PBS to make up a final volume of 20µL were added to each denatured IgG or control 
glycoprotein. Finally, 1µL of the PNGase F (New England BioLabs, 500.000U/mL, #P0704S) 
was added to each tube and mixed gently. The tubes were incubated at 37°C for 1 hour. 
 
35 
 
2.10.2 Non-denaturing Conditions 
20µg of each IgG was mixed with 2µl of GlycoBuffer 2 (10X), 5µL of PNGase F and the 
PBS necessary to make a total reaction volume of 20µl in a 1.5mL Eppendorf tube. The tubes 
were incubated for 24 hours at 37°C.  
 
2.11 Agarose Gel Electrophoresis 
Analysis of the PCR products was performed using agarose gel electrophoresis. 1.5% 
agarose gels were prepared by premixing 150µL of 1XTAE buffer (5-Prime, 50X, #2500060) 
with agarose (Seakem LE Agarose, Lonza, # 5000). After dissolving the agarose in a 
microwave, 7.5µL of Red Safe (iNtRON Biotechnology, #21141) was added to the solution 
when it was at 37°C, mixed and poured into a previously assembled gel tray containing a well-
forming comb. After the polymerization, the tray with agarose gel was placed in a DNA 
electrophoresis chamber containing 1xTAE buffer and the combs were removed. DNA samples 
were prepared by mixing18µL of each DNA sample with 2µL of 10XOrange G loading buffer 
(Life Technologies). Once prepared, the DNA samples were loaded in the correspondent wells 
along with 8µL the molecular weight DNA Marker Ladder III (Nzytech, MB044), for the 
identification of the DNA sizes. The gel was run at 180 Volts for about 45 minutes and the DNA 
bands were visualized under UV light using a BioRad ChemiDoc MP imaging system. 
 
2.12 SDS-PAGE electrophoresis  
For an SDS-PAGE electrophoresis, the Invitrogen pre-cast 4-12% Bis-Tris Gels were 
used (Invitrogen, NuPAGE, NP0321BOX) following the suppliers instructions. Protein samples 
were prepared for running in reducing and non-reducing conditions. Samples were prepared by 
adding 2µg of each IgG, 4µL of 4XLDS (Invitrogen, NuPAGE, NP0007), 1.5µL of 10XReduce 
Agent (Invitrogen, NuPAGE, NP0004), added only for the reducing samples, and PBS to a final 
volume of 16µL. The protein solutions with the reducing agent were heated at 99°C for 5-10 
minutes in a thermostat (Eppendorf thermostat plus). Samples were centrifuged (12000 xg, 1 
minute, RT) and loaded onto the gels along with the 8µL of the molecular weight marker 
Precision Plus Protein Standards All Blue (BioRad, #161-0373). The gel was run at 80 Volts for 
15 minutes and 150 Volts for an hour afterword’s using 1XMOPS buffer (Novex by life 
technologies-NuPAGE, 20X, NP0001). After the run, the gels were stained with Instant Blue 
(expedeon, ISB1L) following the manufacturers protocol. After destaining, images of the gels 
with the protein bands were acquired in the BioRad ChemiDoc MP imaging system. 
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3. Results and Discussion  
 
The presentation of the results is going to be based on the pannings made to select the 
antibodies, where the results of each strategy will be presented chronologically, followed by the 
binding tests performed with the selected scFv and obtained IgGs against the JAG1 
recombinant protein to evaluate their binding ability and specificity. 
 
3.1 Selection of JAG1 scFv antibodies by Phage Display  
3.1.1 1st Library Panning 
The main objective of this thesis was the development of antibodies against the Notch 
ligand JAG1. For that, the phage display technology using the commercially available human 
scFv phage display Tomlinson I+J libraries was used.  
To generate specific antibodies with potential to block JAG1 binding to Notch receptor, 
a truncated version of JAG1 protein designated JAG1-EGF3-Fc, containing the minimal binding 
region of the ligand to the receptor, was used as the antigen in our panning strategies. The 
panning was conducted in immunotubes and the amount of phages used in the first round was 
1013 pfu’s. In order to have the correct conformation of the JAG1-EGF3 protein exposed during 
the scFv selection procedure, it was immobilized via its Fc region to the immunotubes using an 
anti-human IgG-Fc specific Ab. The panning strategy consisted in three rounds of selection with 
the JAG1-EGF3-Fc protein. Each round was preceded by two depletion steps, one using a non-
coated immunotube and another with an immunotube coated with the off-target (anti-human 
IgG-Fc specific Ab + Fc control protein), in order to remove unspecific binders (Figure 3.1). The 
selected phages were amplified between each round. In order to increase the selection 
specificity the amount of the JAG-EGF3-Fc protein was decreased by half in the third round of 
selection. 
 
Figure 3.1- Strategy used for the selection of scFv specific for recombinant JAG1-EGF3 protein. 
For each round of selection, the total amount of phages added (phage input) and 
recovered (phage output) was calculated to determine the percentage of input phage recovery 
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and the enrichment values between rounds.  
 
 
 
Table 3.1. Phage concentration, recovery and enrichment for each round of 1st panning 
 
Panning Round 
Phage Input 
(cfu’s/mL) 
Phage Output 
(cfu’s/mL) 
% of input 
phage recovery 
 
Enrichment 
1st Round 1.3 x 1013 1.4 x 1010 0.1 --- 
2nd Round 7 x 1013 6.8 x 108 9.7 x 10-4 9.7 x 10-3 
3rd Round 2.8 x 1013 2.1 x 108 7.5 x 10-4 0.77 
 
After the first round of selection, it is expected to have a reduction in the number of 
phages due to the fact that a considerable amount of non-binding phages is washed away. On 
the contrary, in the following rounds a gradual increase in the phage concentration should occur 
resultant of the enrichment of the selected phage (Xiaokun Li, 2018). In our panning, the output 
result for the first round was 1.4 x 1010 cfu’s/mL, which is extremely high in comparison to the 
reported values of 108 to 104 (Lai, 2016). Analysis of the results obtained for the second and 
third rounds showed these values were also in the higher range but in acceptable levels with 6.8 
x 108 cfu’s/mL after the second round and to 2.1 x 108 cfu’s/mL after the third round (table 3.1). 
These results indicated that something occurred in the first round. That either the depletion step 
was ineffective or the washing of the immunotube containing the JAG1-EGF3-Fc was not well 
performed, resulting in a high phage output number.  
 
3.1.2 Characterization of selected clones by scFv-on-Phage ELISA 
To evaluate the binding properties of the scFv clones selected from the panning, a 
scFv-on-phage ELISA assay was conducted in 96-wells plates, where the phages from 88 
bacteria colonies from the second and third rounds, picked randomly, were tested for their 
ability to bind the JAG1-EGF3-Fc recombinant protein (non-immobilized, i.e. directly coated, and 
immobilized via its Fc portion). As presented in Figure 1.16, in this library, the scFv are 
expressed as c-Myc tag proteins, and c-Myc is only expressed in phages that are displaying 
their scFv correctly on their cell surfaces. Therefore, in order to evaluate the expression and 
correct display of the scFvs, the presence of c-Myc tag was also assessed by evaluating the 
binding of the selected clones to an anti-c-Myc Ab. Through the detection of the c-Myc tag, we 
were able to identify the clones with good scFv display, and, thus evaluate if the signal 
observed with the recombinant JAG1 and Fc control proteins was in fact related to a specific 
binding between scFvs and the antigen. 
Results from these assays showed that none of the picked clones from the second 
round were expressing the scFv, as evidenced by their absence of binding to the anti-c-Myc Ab 
(i.e. by the absence of c-Myc tag being expressed by the phage)(data not shown). This result 
suggested that probably the TG1 bacteria were not expressing the phages and this could be 
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due to the fact that they were not infected at the correct cell density. This hypothesis was 
supported by the observation that the 96-well plates, in which the bacteria were grown, 
presented some evaporation in the outermost wells that likely affected their growth. Probably 
the correct bacterial density was not achieved impairing the formation of the F-pilus necessary 
for the infection process to occur efficiently. 
From the 88 clones tested from the third round, only 11 were expressing the scFv 
based on the detection of binding to the anti-c-Myc Ab (blue bars in Figure 3.2). This value 
corresponds only to 12.5% of the total amount of clones, which is much lower than what would 
be expected for this library (50-75% scFv display). A positive result was considered when the 
absorbance value measured was 5 times higher than the absorbance value of the negative 
control, which in this experiment corresponded to the uncoated wells. Accordingly, in this 
experiment, signals above or equal 0.3 were considered positive. As shown in Figure 3.2 (green 
and yellow bars) four clones were capable of recognizing specifically the JAG1-EGF3-Fc 
proteins: A3, B3, C3, and C6, presenting high absorbance values. In comparison to clones A3, 
B3, and C6, the clone C3 showed a lower signal, however, we decided to continue to evaluate 
their binding properties since these bound to both JAG1-EGF3-Fc non-immobilized and 
immobilized proteins, and because only few number of positive clones had been obtained in this 
1st panning. The remaining seven clones were discarded because either they did not recognize 
the JAG1-EGF3-Fc protein or also recognized the Fc negative control protein (red bars in 
Figure 3.2). 
Evaluation of the binding ability of the selected JAG1 scFvs to non-immobilized (green 
bars) and immobilized (yellow bars) JAG1-EGF3-Fc proteins showed similar absorbance 
values, indicating that the Fc region does not have an influence on the capacity of the scFv to 
recognize the JAG1-EGF3-Fc protein. The high values obtained with the Fc-oriented protein 
with clones F9 and G5 (yellow bars) are likely mostly due to the recognition of the Fc protein 
fraction and not to the JAG1-EGF3 itself, since they did not recognize the non-immobilized 
JAG1-EGF3-Fc protein but recognized the Fc control protein. The same hypothesis applies to 
the clone F5 (Figure 3.2). 
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Figure 3.2. scFv-on-Phage ELISA of selected clones from round 3 of 1st panning. The graphic shows 
the binding of the indicates clones to non-coated (Nc) wells and wells coated with anti-c-Myc Ab, JAG1-
EGF3-Fc, Fc-oriented-JAG1-EGF3-Fc, and control Fc proteins. Clones A3, B3, C3 and C6 demonstrate 
phage expression, binding towards the JAG1-EGF3-Fc protein and no binding to the Fc protein. 
The JAG1 and DLL1 proteins present a significant degree of homology between their 
EGF regions (Kopan, 2009). Therefore, to ensure that the selected scFv were specific towards 
the JAG1 ligand, their specificity was also tested through an ELISA assay by evaluating their 
ability to bind to truncated DLL1-Fc recombinant proteins. Two different constructs were 
assayed - a DLL1-EGF3-Fc, containing the minimal binding region of the ligand to the Notch 
receptor, and a DLL1-ECD-Fc with the full-length extracellular domain. The binding ability of the 
clones towards the recombinant JAG1 protein with the full ECD – JAG1-ECD-Fc, was also 
evaluated to find out if the presence of the complete ECD would change the protein 
conformation in a way that would impair scFv recognition. A negative control using a non-coated 
plate was also tested. An anti-DLL1 specific scFv, previously selected with the DLL1-EGF3-Fc 
protein by phage display, and capable of recognizing both recombinant DLL1 proteins was used 
as a positive control for the DLL1 proteins. To control the scFv expression and validate the 
results, coating with the anti-c-Myc Ab was also performed. 
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Figure 3.3. scFv-on-phage ELISA specificity assay using JAG1, DLL1 and Fc proteins and anti-c-
Myc Ab. The graphic shows the binding of the indicates clones to non-coated (Nc) wells and wells coated 
with anti-c-Myc Ab, and recombinant Fc, JAG1-EGF3-Fc, JAG1-ECD-Fc, DLL1-EGF3-Fc and DLL1-ECD-
Fc proteins. Clones A3, B3 and C6 demonstrate specificity towards the recombinant JAG1 proteins, 
indicated by the high absorbance value in the JAG1 proteins and residual absorbance values in the DLL1 
ones.  
As illustrated in Figure 3.3, the negative control behaved as expected, validating the 
experiment, by showing no signal in the non-coated wells. Due to the same reason explained 
before, signals with absorbance intensity values 5 times higher the background were 
considered positive. By looking at the results obtained with the anti-c-Myc Ab, corresponding to 
the c-Myc expression and scFv display, we can see that all the evaluated scFv clones are being 
expressed.  
From the Figure 3.3 we can also see that the clone C3, which previously presented a 
reduced signal, again showed a weak signal indicating it may be a very weak binder or a false 
positive clone. However, we decided to continue to study this clone due to the few positive hits 
we had at that time. The remaining A3, B3 and C6 clones confirmed their specificity towards the 
JAG1-EGF3-Fc protein as demonstrated by the ELISA values obtained. However, the signals 
obtained with the JAG1-ECD-Fc protein were significantly lower, suggesting that the presence 
of the full ECD in the protein changes its structure leading to an alteration in the binding 
capacity of the antibody fragments. We can also see that the tested scFv are specific for the 
JAG1 proteins, since they do not bind to the DLL1 recombinant proteins, as evidenced by the 
absence of signal in the wells coated with these proteins. These results suggest that the binding 
site that the scFv recognizes in the JAG1-EGF3-Fc protein is specific for the JAG1 ligand. The 
integrity of the DLL1 proteins was established by the use of the positive scFv control that was 
able to recognize both recombinant DLL1 proteins but none of the JAG1 constructs.  
 
3.1.3 Epitopes ELISA assay  
After selecting the scFv capable of binding to the JAG1-EGF3-Fc protein and evaluating 
their binding properties and specificity, we tried to identify regions within the JAG1-EGF3 protein 
to which they bind by scFv-on-phage ELISA using peptides specific to the DSL and EGF1 
regions, shown to be important in the ligand binding to the receptor (Friec et al., 2012). Binding 
of the anti-JAG1 scFv to specific peptides corresponding to DLS and EGF1 regions of the DLL1 
and JAG2 ligands was also tested, because they present significant homology. In addition, a 
nonspecific peptide was used as a negative control. Since the conformation of the peptides may 
influence the binding of the scFv fragments, two ELISA assays were conducted – one with 
linearized peptides with DTT and another with non-treated/native peptides. 
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Figure 3.4. scFv-on-phage ELISA assay using specific peptides corresponding to the to the DSL 
and EGF1 domais of the JAG1, JAG2 and DLL1 proteins. The graphics in (A) and (B) show the binding 
of anti-JAG1 scFv clones A3, B3, C6 and anti-DLL1 scFv to non-coated (Nc) wells and wells coated with 
native (A) and linearized (B) JAG1-EGF1, JAG1-DSL, JAG2-EGF1, JAG2-DSL, DLL1-EGF1, DLL1-DSL 
and non-specific (Ns PEP) peptides.  
In these experiments, we were not able to identify the specific region to which the scFv bind. As 
shown in Figure 3.4, panel A, using peptides in their native conformation, the difference 
between the signal values of the binding of the various clones to the peptides and the negative 
control peptide are very low in comparison to those obtained in non-coated control wells not 
allowing to conclude if there is any positive result. Besides that, the absorbance values obtained 
with the control non-specific peptide are not significantly different from those obtained with the 
different peptides for JAG1, JAG2 and DLL1 proteins (less than 2-3 times its value), indicating 
that there was no binding between the scFv and the peptides. The results presented in Figure 
3.4, panel B, using the peptides treated with DTT, show the scFv were not capable of 
recognizing the linearized peptides sequences either. These results could suggest that a bigger 
sequence of the JAG1 ligand is necessary for the binding to occur. 
 
3.1.4 Bacterial Growth Kinetics 
As mentioned above, for the infection to occur, bacteria need to develop the F-pilus 
structure (Jacobson, 1972). In the case of the TG1 E. coli strain, the F-pilus is developed 
between a bacterial cell density of 0.4 to 0.5. To assess if the problems we faced during the 
evaluation of the scFv clones selected from the second round were due to a defective infection 
43 
 
because bacteria were not at the correct cell density, a bacterial growth curve assay was 
performed. Several different growth conditions were tested during this experiment.  
We wanted to address if bacterial growth in 96-well plates or falcon tubes would affect 
their development in a significant way.  
 
 
Figure 3.5. TG1 E. coli strain growth curves. TG1 bacteria growth was tested under different conditions. 
In 96-well plates vs. 50 mL falcon tubes; in a small incubator vs. the laboratory main room incubator; 96-well 
plates with 100 µL media inoculated with 10µL vs. 5µL of bacteria; and in a 50 mL falcon tubes with an initial 
OD600nm of 0.05 vs. 0.1. inc, incubator. 
The results from this experiment showed that there was not a significant difference in 
the bacterial growth between the bacteria incubated in 96-well plates and the ones in the falcon 
tubes, with the exception of the 96-well plate inoculated with 5L of bacteria (orange line in 
Figure 3.5, plate/5µL/main inc) that presented a slower growth. These results demonstrate that 
the volume/vessel format used for bacterial cell growth does not have much influence in their 
growth rate. 
Two different incubators in our laboratory were tested, a small one in the “phage-room” 
(Zhicheng) and the other in the main room of the laboratory (Innova44). We wanted to see 
whether the use of different incubators influenced the bacterial growth rate. In Figure 3.5, we 
can observe that in falcon tubes’ experiment, where the only difference is the incubator, there 
are no significant differences in the bacterial growth. However, in the plates we see a different 
situation. When the plates were incubated in the main laboratory (plate/10µL/main inc (yellow) 
and plate/5µL/main inc (orange)), the cultures grew much more slowly when compared to the 
ones that grew in the other incubator (blue and grey lines). This could influence the bacteria 
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infection, since the incubation time needed to achieve the correct OD600nm for infection in this 
last case would need to be higher. Usually, the incubation time before infection varied between 
120 and 150 minutes, and this could mean that while the plate incubated in the main laboratory 
(yellow and orange lines) would have an OD600nm ranging from 0.2 to 0.3, the other plate (blue 
and grey lines) might already have reached the ideal OD600nm of 0.4, and thus be ready for 
infection.  
Another parameter evaluated during this assay was the initial OD600nm of the inoculum. 
Keeping the remaining parameters, we saw that the bacteria inoculated with higher OD600nm 
reached the intended optical density of 0.4 earlier, as expected (Figure 3.5).  
Given this, we decided that all incubations for the panning and ELISA assays would be 
performed in the main laboratory incubator using a starting OD600 nm of 0.05. 
 
3.1.5 PCR and sequencing analysis of the selected anti-JAG1 clones 
3.1.5.1 DNA Extraction 
To further characterize the 4 scFv selected for binding to the JAG1-EGF3-Fc protein by 
scFv-on-phage ELISA, it was necessary to check their DNA sequences for integrity and to 
determine their nucleotide sequences to see if they shared the same sequence or were unique 
clones. DNA from all 4 scFv was extracted using a DNA mini-kit (NZYMiniprep), following the 
protocol provided.  
After the phagemid DNA extraction, the DNA integrity of the 4 clones was analyzed by 
agarose gel electrophoreses. In Figure 3.6 we can see that all clones have a band close to the 
5000 bp that corresponds to the expected size of the pIT2 plasmid containing the DNA 
fragments encoding the scFv Ab (Kenneth Murphy, 2011). This data suggests that the selected 
clones A3, B3, C3, and C6 have the full scFv sequence.  
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Figure 3.6. Agarose gel electrophoresis of plasmid DNA isolated from anti-JAG1 selected clones 
(lanes: A3, B3, C3, C6 clones). The 4 tested clones present a band near the 5000 bp that correspond to 
the size of the plasmid pIT2 with the scFv insert. The remaining bands present in the gel with lower 
molecular weight represent supercoiled versions of the respective DNA clone. Lane: M, Gene Ruler. 
 
3.1.5.2  PCR of the selected clones  
Next a PCR reaction was performed to evaluate the scFvs chain size by using the 
library recommended LMB3, pHEN and Link sequence primers. The LMB3 and the pHEN 
sequence primer pair amplify the entire scFv sequence, containing the variable heavy and light 
chains, permitting to verify if the sequence size matches the expected. Amplification with the 
LMB3 and Link sequence primers allow the amplification of the variable HC, and this way we 
were able to confirm the size of the LC as well. LMB3 primer amplifies the DNA sequence in the 
forward direction, instead of the pHEN and Link sequence primers that do it in the reverse 
direction. 
In Figure 3.7, lanes 5 and E represent our negative controls prepared with no DNA but 
with all the remaining reagents of the experiment. In these lanes no band is observed, meaning 
that no DNA amplification occurred, as expected, validating the experiment.  
In the PCR performed with the LMB3 and pHEN primers, in lanes 1, 2, 3, and 4 in 
Figure 3.7, we can observe a band with a size close to 935 bp, which corresponds to the correct 
size of the full scFv as indicated in the library datasheet. However, in lane 3 the band amplified 
from the clone C3 shows a lower intensity. Moreover, in this lane there is also a PCR product of 
near 600 bp not amplified in the other clones, which suggests a problem with the DNA 
sequence of the C3 clone, that it might comprises several scFv DNAs.  
Analysis of the PCR products obtained with the LMB3 and the Link sequence primers 
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show a band with a size around 527 bp in the lanes correspondent to the clones A3, B3 and C6, 
with similar intensity (lanes A, B, and D in Figure 3.7). This band corresponds to the variable 
heavy chain sequence, according to the library datasheet information. In lane C that contains 
the DNA amplification product from the C3 clone, we can see a very faint band with the same 
size as in the other lanes (A, B and D). The presence of DNA bands with molecular weight 
higher 2000 bp are likely due to some unspecific binding of the primers. Together, these results 
suggest that the selected clones A3, B3 and C6 contains the full size scFv fragment, while the 
clone C3 scFv corresponds to a mix of clones. 
  
  
Figure 3.7. Agarose gel electrophoresis analysis of PCR amplification products of plasmid DNA 
extracted from the selected anti-JAG1 A3, B3, C3 and C6 scFv clones. VH+VL, PCR amplification of 
DNA fragments with VH and VL regions; VH, PCR amplification of VH regions. The PCR conditions were: 
Denaturing stage - 98°C; Annealing stage - 58°C; Extending stage - 72°C. M1, NZY Ladder III; M2, Gene 
Ruler.  
3.1.5.3  DNA Sequencing of the selected clones 
The DNA sequencing reaction was performed at the GATC company. For each clone, 
three reactions were performed using three different primers to ensure that the entire scFv 
nucleotide sequence was identified in both orientations. The LMB3 primer allows amplification 
of the scFv sequence from the 5´end beginning in the forward direction. The pHEN sequence 
primer amplifies the scFv sequence from the 3´ end in the reverse direction. The Link sequence 
primer amplifies the scFv sequence from the middle of the sequence in a reverse direction.  
After the DNA sequences were determined, the sequences were analyzed using the 
Clone Manager and Chromas software. Analysis of the DNA sequences of clones A3, B3 and 
C6 confirmed they contained the full-length scFv sequence and revealed their DNA sequences 
were identical. DNA sequencing analysis of the C3 clone showed the presence of overlapping 
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nucleotides in the CDR regions indicating a mix of clones, as suggested from the PCR results. 
This observation might explain the low binding ability of this clone in comparison to the A3, B3 
and C6 clones as observed in the ELISA assays (Figures 3.2 and 3.3). 
The different clones within the C3 clone were segregated by plating various dilutions of 
this clone in 2YT-agar plates and analyzing the binding ability of the phages from the various 
resulting colonies to the JAG1-EGF3-Fc protein by ELISA as above. The results from these 
assays showed that none of the C3-segregated clones bound to the JAG1-EGF3-Fc protein 
(data not shown), suggesting the loss of the JAG1-EGF3-Fc-binding scFv clone within the C3. 
Another explanation is that the C3 was a false positive, a hypothesis supported by its low 
binding ability towards the JAG1-EGF3-Fc protein observed in the ELISA assays. 
Altogether, these results showed we had one unique scFv sequence capable of 
recognizing the JAG1 protein. 
Analysis of the amino acid sequences encoded by the scFv DNA fragment of the clones 
A3, B3, and C6, revealed the presence of an asparagine residue in the CDR2 of the HC 
(HCDR2), which can be glycosylated in the IgG format. Since glycosylation of CDR regions 
compromises the binding of the IgGs to the respective antigens, as it alters de Ab kinetics, 
stability and function (Mo et al., 2018), the identified scFv was reformatted into two IgGs: IgG48 
where the HCDR2 asparagine residue was replaced by a glutamine, and IgG49 with the 
asparagine residue within the HCDR2. Bayer kindly supported the reformatting procedure of the 
scFv into the IgG format that were produced in mammalian cells and purified by 
chromatography. 
 
3.1.6 Characterization of the generated anti-JAG1 IgG48 and IgG49 from 
the selected anti-JAG1 scFv 
3.1.6.1 Characterization of anti-JAG1 IgG48 and IgG49 by ELISA 
After reformatting the unique selected scFv resulting from the 1st panning into an IgG, 
ELISA assays were done to evaluate the binding properties towards the JAG1-EGF3-Fc 
recombinant protein. As mentioned above two IgGs were produced from the scFv sequence: 
the IgG49 containing the asparagine residue in the CDR2 of the HC; the IgG48 with the 
replacement of the asparagine in the CDR2 of the HC to a glutamine, to understand if the 
glycosylation of the IgG could affect its binding ability.  
A dose response assay, using 2-fold-serial dilutions of each IgG with initial 
concentration of 100µg/mL, was performed to titrate the antibody towards the JAG1-EGF3-Fc 
protein, to allow understanding the optimal concentration at which the IgG would recognize the 
recombinant JAG1-EGF3-Fc protein. As in previous ELISA assays the Fc recombinant protein 
was used as a negative control. Non-coated wells were also used as negative controls to 
assess unspecific binding to the plastic. In these assays, the secondary antibody/detection Ab 
was used at 0.25µg/mL and 2.5µg/mL to evaluate which dosage produced better results with 
less background interference. An ELISA assay performed with a protein P and its specific 
detection antibody was also performed as a positive control for the ELISA assays. 
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Figure 3.8. ELISA of IgG48, IgG49 and Protein P. (A-B), ELISA measurement binding assay of anti-
JAG1 IgG48 and IgG49 to JAG1-EGF3-Fc protein. Non-coated (Nc) and coated wells with 5µg/mL of 
JAG1-EGF3-Fc or Fc control proteins were incubated with different concentrations of anti-JAG1 IgG58 (A) 
or IgG59 (B). (C), wells were coated with 5µg/mL of protein A and were incubated with various amounts of 
anti-protein P antibody. IgG binding in A, B, an C was detected using 2.5g/mL (filled symbols) or 
0.25g/mL (open symbols) of the secondary antibody.  
Data presented in Figure 3.8 (panels A and B) on the binding of IgG48 and IgG49, 
respectively, show that these IgGs do not recognize the JAG1-EGF3-Fc protein at any tested 
concentration and condition. 
Analysis of the binding ability of the anti-Protein P to its target protein (Figure 3.8, panel 
C) showed a dose-response curve with both concentrations of the secondary Ab (0.25µg/mL 
and 2.5µg/mL), indicating the anti-Protein P recognized its target antigen, validating the ELISA 
assay. However, when using a concentration of 2.5µg/mL of the secondary Ab we saw very 
high absorbance values. This indicates that the concentration of the secondary Ab should be 
lower than 2.5µg/mL. 
Evaluation of the JAG1-EGF3-Fc protein quality in cellular assays showed it induced 
the expression of Notch-target genes (data not shown) confirming the good protein quality, 
indicating that the absence of binding of the IgG48 and IgG49 is not due to improper quality of 
the antigen. Indeed, a loss of binding capacity can occur after reformatting a scFv into an IgG 
due to some structural orientations that can make inaccessible the local of binding from the IgG. 
Another explanation is the presence of glycan groups in the IgG’s that could block the access to 
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the recombinant JAG1 protein (Lee et al., 2017).  
 
3.1.6.2 SDS-PAGE analysis of anti-JAG1 IgG48 and IgG49 
Given the above results, next the anti-JAG1 IgG48 and IgG49 were analyzed by SDS-
PAGE in reducing and non-reducing conditions to confirm their integrity, quality, and the 
potential presence of post-translational modifications. In reducing conditions, 2 bands should be 
detected: one band with a molecular weight of 50 kDa, corresponding to the heavy chains, and 
another band with 25 kDa, corresponding to the light chains, due to the break of the disulfide 
bonds that connect all the chains. In the non-reducing conditions, a single band of 150 kDa, 
corresponding to the entire Ab should be detected.  
 
 
 
 
Figure 3.9. SDS-PAGE analysis of the reduced and non-reduce forms of the anti-JAG1 IgG48 and 
IgG49. Two bands in both IgGs in the non-reducing conditions suggest the existence of a high molecular 
weight (HMW) version of the IgGs. The presence of two bands near the 25 kDa in reducing conditions, 
corresponding to the LC, also suggests the existence of a HMW version of the LC. M-Precision Plus 
Protein Standard marker All blue. R, Reduced samples; NR, Non-reduced samples. 
As shown in Figure 3.9 in reducing conditions both IgGs show the presence of three 
bands: a band of 25 kDa that corresponds to the LC; a band slightly above the 25 kDa that 
should also correspond to a LC variant; and a higher molecular weight band corresponding to 
the HC, with the expected 50 kDa in the IgG48 and a slightly higher molecular weight in the 
IgG49. The presence of a higher molecular weight HC in IgG49 was expected since it contains 
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a glycosylation site in the HCDR2. In non-reducing conditions, two bands are detected in both 
IgG samples instead of one. A band near the 150 kDa corresponding to the entire IgG and a 
second band with a significantly higher molecular weight that should also correspond to the IgG. 
These observations together suggest that both IgGs are glycosylated, since 
glycosylation confers higher molecular weights to IgGs (Zheng et al., 2011). The presence of 
two bands in both IgGs in the non-reducing conditions indicates that not all Ab molecules from 
the same IgG are glycosylated, this could mean that the higher molecular band corresponds to 
the glycosylated Ab fraction and the 150 kDa band to the non-glycosylated forms. In the 
reduced IgGs, the presence of a fainter band above the 25 kDa suggests that both antibodies 
also contain glycosylated light chains. The higher molecular weight of the heavy chain of IgG49 
in reducing conditions, in comparison to that of IgG48, indicates that IgG49 is more glycosylated 
than IgG48. This result was expected based on the amino acid sequence of the scFv and may 
indicate that the removal of the glycosylation site in the IgG48 heavy chain was successful. 
 
3.1.6.3 Glycosylation analysis of the anti-JAG1 IgG48 and IgG49 with 
PNGase F 
To evaluate if the existence of three bands in reducing conditions and two bands in non-
reducing conditions in the SDS gel above (Figure 3.9) was due to a glycosylation modification of 
the IgGs, a deglycosylation reaction assay, was conducted using PNGase F enzyme. In this 
assay, the IgGs were incubated with the PNGase F enzyme, responsible for removing the 
glycan groups by cutting between an N-Acetylglucosamine and an asparagine residue of high 
mannose, hybrid, and complex oligosaccharides from N-linked glycoproteins.  
This experiment was done using denaturated and non-denatured IgGs, as 
recommended by the enzyme supplier. As a negative control, samples of the IgG were 
incubated with the reagents without the PNGase F enzyme. As a positive control for the 
reaction conditions and functioning of the enzyme, the assay was also performed with a 
glycoprotein recommended by the enzyme suppliers. When the reactions were complete, the 
digestion products were analyzed by SDS-PAGE in reducing conditions. IgG samples in 
reduced and non-reduced forms were compared with the denaturated samples that resulted 
from this experiment (with and without PNGase F enzyme). 
As shown in Figure 3.10, a similar pattern is observed between the reducing sample 
and the IgG denaturated and reduced sample without the enzyme as expected, due to the 
permanence of the glycan groups in the IgGs. We can observe two bands in the non-reduced 
sample that corresponds to the full glycosylated IgG and lacking any glycan groups. From the 
three bands observed in the reduced wells one correspond to the HC (near 50 kDa) and the 
other two bands to the LC, in which the band with higher molecular weight corresponds to the 
glycosylated LC. Comparison of the bands correspondent to the 50 kDa in the reducing wells 
from IgG48 and IgG49 shows that the band from the IgG49 is slightly higher than the IgG48 
one. 
When the PNGase F enzyme is added to the solution, it removes the glycan groups 
from the IgGs, and this is demonstrated by the absence of two bands near the 25 kDa MW but 
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rather only one is detected, and the 50 kDa band suffers a small decrease in molecular weight 
also consistent with the removal of the glycan groups. 
In the control glycoprotein gel we can see a single band with a lower molecular weight 
(around 18 kDa) in the sample incubated without the PNGase F enzyme, and when we 
compare it to the sample treated with this enzyme we observe a decrease in the molecular 
weight, indicating reaction efficiency. Moreover, since we only see one band, we can say that 
the deglycosylation was complete and the reaction conditions were optimal, at least for this 
protein. The appearance of a new band in the samples containing the enzyme is due to the 
presence of PNGase F that has a molecular weight near the 35 kDa. In denaturing conditions, 
the deglycosylation was complete.  
These results, showing only two bands near 50 and 25 kDa upon treatment with 
PNGase F enzyme demonstrate that the bands with atypical sizes in the SDS-PAGE in non-
reducing and reducing conditions corresponded to glycosylated variants of both IgGs. 
 
Figure 3.10. SDS-PAGE of denaturated IgG48 and IgG49 untreated and treated with PNGase F 
under reducing conditions. IgG samples present two bands in the gel approximately at 150 and 200 kDa 
in the non-reducing conditions, correspondent to the full IgG with high molecular weight (HMW) and with 
150 kDa. In the samples incubated under reducing conditions three bands in the gel are detected, one 
correspondent to the HC and two to the LC with different molecular weights. The same band pattern is 
observed in denaturated samples not-incubated with the PNGase F enzyme. In the denaturated samples 
treated with PNGase F three bands are detected in the gel with a different pattern. Samples treated with 
the enzyme, when compared to the untreated sample, show a decrease in the molecular weight of the 
band correspondent to the HC. Also, the band correspondent to the LC (HMW) disappears, and the LC 
band in the 25 kDa seems to become bigger. The control glycoprotein presents a decrease in the 
molecular weight in the sample treated with the PNGase F enzyme, validating the assay. The bands 
observed in the gel near the 35 kDa correspond to the PNGase F enzyme in the solution. M, Precision 
Plus Protein Standard marker All Blue; R, Reduced.NR, Non-reduced; -, without PNGase F enzyme; +, 
with PNGase F enzyme. 
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However, in Figure 3.11, corresponding to samples treated with PNGase F enzyme in 
non-denaturing conditions, we see different results. The deglycosylation of the HC was 
complete in the IgG48, as shown by the decreased sizes of the band at 50 kDa, but not in the 
IgG49 observable by the difference in the molecular weight of both samples treated with 
PNGase F. The molecular weight difference between both IgGs could indicate that the IgG49 
has more glycan groups then the IgG48 because in both samples, treated and non-treated with 
PNGase-F, the bands of the IgG49 presented a higher molecular weight. The LC remained 
glycosylated in both IgGs, proven by the presence of two bands near the 25 kDa, where the 
band with the highest molecular weight corresponds to the glycosylated version of the LC. This 
could be related with to the PNGase F reaction time that might not have been enough for the 
complete removal of the glycans to occur under non-denaturing conditions, or more probably, 
because the glycosylation site was not accessible to the PNGase F enzyme thus impairing the 
efficient removal the glycan group (Rudd et al., 1997). 
 
 
Figure 3.11. SDS-PAGE of native IgG48, and IgG49 untreated and treated with PNGase F under 
reducing conditions. Relative to control untreated proteins in reducing conditions, reduced IgGs treated 
with the PNGase F enzyme under native conditions show a decrease in the molecular weight of the HC 
band but not in the LC bands. The band near the 35 kDa correspondent to the PNGase F enzyme.. M, 
Precision Plus Protein Standard marker All Blue; -, without PNGase F; +, with PNGase F. 
 
3.2 Selection of JAG1 scFv antibodies by Phage Display  
3.2.1 2nd Library Panning 
Considering the poor results obtained in the 1st panning, we pursued a series of tests to 
try to discover its origin and we concluded that it was due to library aliquots used. The inputs 
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and outputs of library pools used for the panning were analyzed. The pools used for the 1st 
panning selection had been previously submitted to several amplifications, and also to repeated 
freezing and thaw cycles, and this can lead to significant drops in the library titers. Because of 
that, new aliquots of the Tomlinson library with higher quality and titers, and only one 
amplification process, were obtained from collaborators from Maastricht University to perform 
another panning.  
With the new aliquot we perform another panning using the same strategy as above, 
with three rounds of selection using the recombinant JAG1-EGF3-Fc protein immobilized via its 
Fc region, preceded by three depletion steps with non-coated immunotubes, as well as 
immunotubes coated with the off-targets - anti-human IgG-Fc specific Ab plus Fc control protein 
- to allow removal of unspecific binders. The selected phages were amplified between each 
round (Figure 3.1). 
During the panning, we used 25µg/mL of recombinant protein JAG1-EGF3-Fc in the 
first and second rounds and 12.5µg/mL in the third round, to enforce specific selection. The 
proteins used in the depletion step were used at the same concentrations as the JAG1-EGF3-
Fc protein. The concentration of phage in the output after each round was evaluated after 
titration. 
 
Table 3.2. Phage concentration, recovery and enrichment after each round of selection from the 2nd 
panning. 
 
Panning Round 
Phage Input 
(cfu’s/mL) 
Phage Output 
(cfu’s/mL) 
% of input 
phage recovery 
 
Enrichment 
1st Round 2.5 x 1012 1.3 x 107 5.2 x 10-4 --- 
2nd Round 1.1 x 1013 3.5 x 107 3.2 x 10-4 0.6 
3rd Round 5 x 1012 2.9 x 107 5.8 x 10-4 1,8 
 
As we can see in table 3.2, our results show that the outputs obtained were in the 
expected range with values varying from 1.3 to 3.5 X 107 cfu’s/mL throughout the rounds of 
selection. We can clearly see an improvement, especially after the first round of selection, in 
which before in the 1st panning we obtained an extremely high titer of 1010 cfu’s/mL. These 
results indicate that the new aliquots of the Tomlinson library were in better conditions.  
Moreover, in this strategy, the output concentration of the phages remained similar 
throughout rounds, suggesting that the enrichment of the JAG1-EGF3-Fc binding phages might 
not have happen as expected. However, to better assess this fact scFv-on-phage ELISAs were 
performed. 
 
3.2.2  Analysis of scFv expression and specific binding towards JAG1-
EGF3-Fc by scFv-on-phage ELISA 
After the panning, E.coli bacteria were infected with the outputs from the second and 
third rounds. 88 clones from round 2 and 352 clones from round 3 were tested by ELISA assay, 
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in order to select specific scFv clones against the antigen JAG1-EGF3-Fc. To validate the 
experiment the scFv expression/display was confirmed by using an anti-c-Myc Ab. 
Five 96 well plates were picked for scFv-on-Phage ELISAs assessment - 1 plate from 
round 2 and 4 plates from round 3. The ELISA results allowed to identify 80 scFvs positive 
clones capable of binding specifically to the JAG1-EGF3-Fc protein. This much higher number 
of positive scFv clones clearly demonstrates that in the 1st panning, where only 4 positive scFv 
clones were identified, the poor results were due to the low quality and reduced titers of the 
phage library aliquots used. Another result supporting this conclusion is the increase observed 
in the expression of the scFvs, which rose from 12.5% from the 1st panning to near 70% for the 
2nd. 
ELISA data from the second round of the panning, represented in Figure 3.12, panel A, 
shows that only 2 out of the 88 clones tested recognized the JAG1-EGF3-Fc protein. This value 
is quite low and indicates that two rounds of selection are not enough to have a phage pool 
enriched for JAG1, and thus more rounds of selection are needed to accomplish that. The 
phage expression obtained was in the 64% level. 
In the first ELISA made with the clones from the third round of selection, 21 scFv were 
able to recognize the JAG1-EGF3-Fc recombinant protein, as we can see in Figure 3.12, panel 
B. This plate presented a 65% rate in phage expression. In the second ELISA made with phage 
pools selected from the third round (Figure 3.12, panel C) 9 scFv seem to recognize the target 
protein. In this assay the signals correspondent to the JAG1-EGF3-Fc protein were very low 
and the Fc signals seem very similar to these ones, suggesting the identified clones might be 
false positives. Despite that, we decided further test them. In this assay the incubator turned off 
during part of the period affecting the bacteria growth and the phage production, a fact that 
might explain the poor results herein obtained. 
In the third and fourth ELISAs made with clones from the third round of selection (Figure 
3.12, panels D and E) we had expression levels of 74 and 58% respectively, and were able to 
identify more 48 scFv able to recognize the JAG1-EGF3-Fc protein. Altogether, this assessment 
allowed identifying a total of 80 scFv capable of binding to the JAG1-EGF3-Fc protein and these 
were selected for further testes. 
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Figure 3.12. scFv-on-phage ELISA of clones from the 2nd panning that bound to JAG1-EGF3-Fc 
protein. The graphics show the binding of the anti-JAG1-EGF3-Fc scFv binders obtained from the second 
(A) and the third (B-E) rounds of selection to non-coated (Nc) wells and wells coated with anti-c-Myc Ab, and 
JAG1-EGF3-Fc and Fc proteins. 
 
3.2.3 Binding ability of selected scFv from 2nd panning towards 
recombinant JAG1 and DLL1 proteins by scFv-on-phage ELISA  
The next step was the confirmation of the previous ELISA results. For that a scFv-on-
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phage ELISA assay with all the 80 selected scFv from the previous scFv-on-phage ELISA was 
done. To do that, anti-JAG1-EGF3 scFv clones resulting from the second and third pannings 
were picked from the glycerol stock plates and inoculated into a new plate (re-array plate) to be 
amplified and expressed as indicated in the material and methods section. Then, their binding to 
JAG1-EGF3-Fc recombinant protein was evaluated. As positive control for the anti-JAG1 scFv, 
we used the A3 positive scFv clone selected in the 1st panning. Two assays were conducted. 
One to evaluate the binding of the selected clones to both recombinant JAG1-EGF3-Fc and 
JAG1-ECD-Fc proteins. Another to evaluate the specificity of the anti-JAG1 scFv towards JAG1 
protein in which the DLL1-EGF3-Fc protein was also used to test for eventual cross-reactivity to 
another Notch ligand. As in the previous ELISA assays, uncoated wells were used to set the 
minimal absorbance background, and wells coated with Fc proteins were used as negative 
control. As before, a coating with an anti-c-Myc Ab was also done to control for the scFv 
expression and validate the results. 
Results from the first assay showed that, from the 80 anti-JAG1-EGF3 scFv 22 no longer bound 
to the JAG1 recombinant proteins, even though they were being expressed according to the 
absorbance values obtained with the anti-c-Myc antibody (Figure 3.13). These results leaded to 
the hypothesis that these 22 scFvs were most likely false positive that gave wrong signals in the 
first assay, and as such they were discarded. Moreover, results from these assay show that the 
scFv recognizing the JAG1-EGF3-Fc protein also recognize the recombinant JAG1 protein 
containing the full ECD (i.e. JAG1-ECD-Fc). 
 
Figure 3.13. scFv-on-phage ELISA assay using JAG1-EGF3-Fc, JAG1-ECD-Fc, and Fc proteins and 
anti-c-Myc Ab. The graphics show the binding of the anti-JAG1-EGF3-Fc scFv obtained from the 2nd 
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panning. 
Results from ELISA assay performed with the recombinant DLL1-EGF3-Fc protein 
showed that 3 other scFv clones were recognizing the DLL1-EGF3-Fc or the Fc proteins (clones 
E2, E4 and F6 in Figure 3.14), making them unspecific for the JAG1 ligand and due to that fact 
they were discarded. 
 
 
Figure 3.14. scFv-on-phage ELISA specificity assay using JAG1-EGF3-Fc, DLL1-EGF3-Fc and Fc 
proteins and anti-c-Myc Ab. The graphics show the binding of the anti-JAG1-EGF3-Fc scFv obtained 
from the 2nd panning. 
In conclusion, analysis of the results from the ELISA assays performed with clones selected 
from the 2nd panning allowed the identification of 55 clones able to specifically recognize the 
JAG1 recombinant proteins (Figure 3.15). 
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Figure 3.15. scFv-on-phage ELISA confirmation of clones from the 2nd panning that bound to 
JAG1EGF3-Fc protein. The discontinuous line in black represents the minimum absorbance value for 
which a result was considered positive. 
 
3.2.4 DNA Sequencing 
In order to determine the unique clones and evaluate their integrity, the scFv DNA 
sequence of the 55 selected clones against the JAG1 proteins, identified above, was 
determined using the LMB3, pHEN and Link sequence primers. Sequencing was performed by 
an outsourced company. 
Analysis of the resulting DNA sequences from the 55 scFv clones, considering the 
differences in the variable region of both heavy and light chains, permitted the identification of 
19 unique scFv sequences, all of them containing the complete scFv nucleotide sequence. Out 
of these 19 unique sequences, 7 scFv clones presented no glycosylation sites in the variable 
regions and were selected for subsequent reformatting into IgGs. The remaining 12 unique 
clones contain glycosylation sites in their CDR regions: 7 clones with 1 glycosite; 5 clones with 
2 glycosites. These clones were discarded since the presence of glycosites in the CDR regions 
of the antibodies can lead to an impairment of the binding of these molecules to their target, 
even if certain residues are deleted or replaced by amino acids found in the germline CDRs 
(Lee et al., 2017). Of note, this was the case of the unique clone identified during the 1st 
panning, that bound to the JAG1 recombinant proteins in the scFv format but not in the IgG 
format (Figures 3.2, 3.3 and 3.8). 
 
3.2.5 Flow Cytometry 
3.2.5.1 Binding of scFv to endogenous cellular JAG1 protein 
An evaluation of the binding properties of the scFv towards JAG1 protein in cells was 
also tested, as a first attempt, to see if they were able to recognize the native cellular protein. 
The capacity of the scFv to recognize endogenous JAG1 protein was tested using two cell lines: 
MDA-MB-231 triple negative breast cancer cells that express high JAG1, and the MCF-7 luminal 
A BC cells expressing very low JAG1 levels (Figure 3.14). 
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Results from this experiment, presented in Figure 3.15, showed that some of the scFv 
bound to the MDA-MB-231 cells and not to the MCF-7 ones, as reflected by an increase in the 
fluorescence signal in the MDA-MB-231 cells in comparison to MCF-7 cells and control cells 
treated with secondary Ab alone. The exceptions were the clones A09 and F12 that increased 
the fluorescence signal in MCF-7 cells. 
Given the much higher JAG1 expression in the MDA-MB-231 cells relative to MCF-7 
cells this data might suggest that the significant increase in the fluorescence value obtained in 
MDA-MB-231 cells incubated with anti-JAG1 scFv clones is due to their specific binding to the 
JAG1 cellular protein.  
 
Figure 3.17. Fluorescence levels of MDA-MB-231 (JAG1 high expression) and MCF-7 (JAG1 very 
low expression) cell lines incubated with the indicated anti-JAG1 scFv clones. The MDA-MB-231 
cells incubated with the indicated clones present higher fluorescence levels when compared with the MCF-
7 and control cells treated with secondary Ab (2ary CTR Ab) with the exception for the A09 and F12 scFv 
clones. The discontinuous line in black represents the minimum fluorescence value for which a result was 
considered positive. 
To validate these results, a scFv-on-phage ELISA was performed using the anti-c-Myc 
Ab as a control for the expression of the scFvs. Figure 3.16 shows that the majority of the scFvs 
Figure 3.16. JAG1 mRNA expression levels in MCF-7 
and MDA-MB-231 cell lines. Expression of JAG1 mRNA 
levels in luminal A MCF-7 and triple-negative MDA-MB-231 
breast cancer cells were quantitated by qRT-PCR. The 
JAG1 mRNA values were normalized against the 
housekeeping gene HPRT1 mRNA levels in the same 
samples.  
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were being expressed, validating the results in terms of their binding to MDA-MB-231 cells. The 
exceptions were the C4 and C5 clones that did not express the c-Myc protein but bound to 
MDA-MB-231 cells possibly due to unspecific binding of some bacterial remains to the plastic or 
a problem with their expression.  
In order to validate these results, and clearly assess the specific binding of the anti-
JAG1 scFv clones to cellular JAG1 a stable CHO-K1 cell line overexpressing human JAG1 
(CHO-k1/JAG1+) and a negative control cell line without human JAG1 (CHO-k1/control vector) 
was recently generated in the laboratory. 
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Figure 3.18. Fluorescence levels in the MDA-MB-231 cells incubated with the indicated anti-JAG1 
scFv clones vs. their expression levels determined by scFv-on-phage ELISA. The majority of anti-
JAG1 scFv clones that bind to MDA-MB-231 cells display their scFv as detected by ELISA. The exceptions 
are the C04 and C05 clones. 
 
 
 
 
 
 
 
 
61 
 
4. Conclusions and Future Perspectives 
 
In summary, the work performed during this thesis allowed the selection by phage 
display of 84 scFv antibody fragments capable of recognizing the JAG1 protein. Evaluation of 
their binding properties towards JAG1 recombinant proteins by ELISA confirmed the selection of 
55 anti-JAG1 scFvs. Sequencing analysis of these clones led to the identification of 19 unique 
anti-JAG1 scFvs. Out of these 19 unique sequences, 7 scFv clones present no glycosylation 
sites in the variable regions. Therefore, the two first goals of this thesis were achieved. ELISA 
assays performed with different peptides of conserved JAG1 regions, however, did not allow 
identifying the epitope regions of the selected anti-JAG1 scFvs. 
One of the identified anti-JAG1 scFv, containing a glycosylation site in the HCDR2 
region, was reformatted into 2 IgGs - one with a glycosite in HCDR2 and the other without. 
Characterization of these IgGs by ELISA showed that none of them recognized the JAG1 
protein. SDS-PAGE and glycosylation assays indicate that both IgGs contain glycosylated 
variants. 
In the future, the 7 unique anti-JAG1 scFvs without glycosites in their HCDR2 regions will be 
reformatted into IgGs, produced in mammalian cells, and purified using chromatography 
techniques. The generated IgGs will be then characterized in terms of their binding ability and 
affinity towards recombinant JAG1 proteins by ELISA and by flow cytometry to cellular JAG1 
using a CHO-K1 stable cell line overexpressing human JAG1. Thereafter, the cellular effects of 
the specific anti-JAG1 IgGs will be assessed in cellular models of TNBC cells. 
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